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Abstract 
Genomic expression studies are the means of depicting molecular 
profiles characterizing specific disease states. Microarrays allow 
the tracking and the translation of genome sequences into gene 
functions, leading to the identification of highly informative genes 
and pathways with a potential impact on understanding disease 
development and progression. These technologies concurrently 
may improve diagnostic and treatment modalities and the detec-
tion of novel therapeutic targets. 
Expression array technology is dramatically expanding the 
amount of data available on many disease states. These studies 
typically involve many researchers with different backgrounds, 
each contributing to some steps of the entire process.  
In particular, Tissue Microarray technology allows for high-
throughput expression profiling of tumor samples by evaluating 
potentially interesting candidate genes and proteins on a large 
number of well-characterized tumors, providing information on a 
population basis.  
High quality experimental data production is extremely important 
for the reliability of data analysis. Critical assessment of experi-
mental design and organization and reliability assessment of ex-
perimental data together with data preprocessing need to be ad-
dressed. A technological approach is also advisable to properly 
manage data heterogeneity, data quantity and user diversity. 
The focus of this thesis is to develop a systematic approach to 
processing and better understanding data generated from Tissue 
Microarray technology, overcoming the limitations of other cur-
rent approaches. This thesis addresses Tissue Microarray data 
collection and organization, enhancing data sharing, usability, 
and process automation. We faced pre-processing issues, identify-
ing critical points and some solutions. We also focused on a spe-
cific issue in data classification, proposing a novel classification 
model based on a Bayesian hierarchical approach, able to handle 
data uncertainty. Three Tissue Microarray experiments are pre-
ii 
 
sented as case studies with the purpose of providing real world 
examples to illustrate some of the critical points made in this the-
sis. 
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1. Introduction 
This doctoral thesis addresses how to handling gene and protein 
expression information, obtained by using a high throughput 
technique, called Tissue Microarray Technology. It encompasses 
the interdisciplinary field of bioinformatics. This chapter first in-
troduces the headlines of this discipline. 
 
Bioinformatics uses techniques and concepts from informatics, 
statistics, mathematics, chemistry, biochemistry, physics, and lin-
guistics and has many practical applications in different areas of 
biology, medicine and informatics. Generally speaking, all 
knowledge which can be extracted from computer analysis of bio-
logical data may be labeled as bioinformatics.  
Therefore, as bioinformatics is really an heterogeneous and rap-
idly evolving field, it might be helpful to sub-divide its current 
possible different activities by key areas to organize concepts 
[1][2], keeping in mind that the individual research activity often 
embraces more than one area in a comprehensive transversal way. 
Bioinformatics could be divided into the following key areas: 
 
I. Sequencing (Algorithms for DNA, genomic 
and protein sequences, Algorithms for sequence 
comparison and multiple sequence alignment) 
II. Organization of Biological Knowledge (De-
velopment of database for bio-structure and bio-
processes organization, Infrastructure for distrib-
uted resources, User Interface and Information 
Representation, Query Languages, Networks, 
Taxonomy and Ontology). 
III. Knowledge Discovery & Data Mining (Algo-
rithms for feature selection for gene reduction, 
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Learning algorithms for gene and protein expres-
sion). 
IV. Biomolecular structure and Biological proc-
esses (Computational Structure Biology, Compu-
tational Systems Biology).  
 
As suggested by Luscombe et al. [3] the development of bioin-
formatics techniques has essentially determined an expansion of 
biological research in two dimensions, each one with specific 
aims and related view of biological problems. Working in each of 
these two dimensions often requires the use of tools and knowl-
edge specific to the four key areas of bioinformatics as defined 
above. The aim of the first dimension is to fully understand the 
information contained by individual genes. In this sense bioin-
formatics follows more the traditional reductionistic approach that 
was typical of biological studies. Starting with a gene sequence, 
the encoded protein sequence can be determined with strong cer-
tainty. Next step is to calculate the structure adopted by the pro-
tein. Finally, docking algorithms could design molecules that 
could bind the model structure, leading the way for biochemical 
assays to test their biological activity on the actual protein. So this 
dimension may be labeled as “rational drug process design”. In 
this context, clinical validation of a new gene potentially impor-
tant in disease development and progression, as indicated in gene 
expression experiments, has a crucial role, allowing for the identi-
fication of novel therapeutic targets. 
The second dimension refers information related to the systemic 
functional behavior of the cell or the organism. It is possible to 
distinguish an experimental and a theoretical approach. The for-
mer organizes biological knowledge principally by experimen-
tally and computationally searching for similarities between dif-
ferent molecules. This allows for the transfer of information 
between related entities and eventually leads to gene discovery or 
protein families, which share structures and/or functions. In this 
way, biologists are able to compile a “genome census” that pro-
vides comprehensive statistical accounts of protein features, such 
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as the abundance of particular structures or functions in different 
genomes. Using this data it is also possible to trace the evolution-
ary path of proteins, gaining first insights into the evolutionary 
path of the whole organism. Expression microarray data repre-
sents a rapidly growing and exciting new source of genomic in-
formation. Grouping genes with similar expression profiles is a 
typical operation of this second dimension. In this way it is possi-
ble to help physicians improve disease classification leading to 
advances in diagnosis, prognosis and therapeutic treatment.  
 
In theory, biological systems may be studied following a systemic 
approach, dividing biological information into two areas: (i) 
genes, proteins and individual molecules as basic components of 
biological systems; (ii) regulatory networks (which specify the 
expression patterns of genes and proteins), intracellular metabolic 
networks and both intra- and inter-cellular communication net-
works, in which molecules participate. This biological informa-
tion is hierarchical. An important emerging challenge for biology 
and medicine is the study of complex biological systems by cap-
turing and integrating these different levels of biological informa-
tion, thus scaling up from molecular biology to systems biology. 
An integrated and more global view of the systems requires the 
application of models to hierarchically understand the interplay 
between atoms, molecules, regulatory and metabolic processes, 
and cells to help simulate or analyze dynamic behavior of bio-
logical systems. The ultimate goal of systems biology is to cor-
rectly understand the complex biological networks that define a 
cell response to environmental and genetic changes, therefore to 
correctly predict and modify the behavior of biological systems.  
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Figure 1 - Bioinformatics as interdisciplinary framework 
 
1.1. The Context 
Gene expression is the process by which genetic information is 
converted into the structures and functions of a cell, by producing 
proteins from DNA coding sequences. The amount of protein that 
a cell expresses depends on the tissue, on the developmental stage 
of the organism and on the metabolic or physiologic state of the 
cell. Molecular profiles, which represent the molecular fingerprint 
of cells, are investigated to depict profiles characterizing specific 
diseases [4].Molecular profiling studies are primarily conducted 
in a comparative manner. Molecular profiling can be based on 
comparison between non-diseased (i.e., normal) and diseased 
(e.g., tumors) samples, between diseased samples pharmacologi-
cally treated and untreated at variable time points or between 
samples of different diseases. 
 
Expression array technology is dramatically expanding the 
amount of data available on many disease states. This technology 
allows tracking the translation of genome sequences into gene 
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functions (functional genomics). In the study of cancer, this new 
biological knowledge promises to improve diagnostic [5][6] and 
prognostic modalities [7][8][9] and to detect targets for new 
therapies [10]. 
Microarrays generate large molecular datasets in the setting of 
similar experimental conditions: DNA microarrays (DMAs) (first 
proposed in 1996, [11]) analyze mRNA expression, and Tissue 
microarrays (TMAs) (first proposed in 1998, [12]) evaluate DNA, 
RNA or protein targets through in situ investigations (analyses 
performed on tissues) by hybridization or immunhistochemistry. 
In molecular profiling studies of human cancer, integration of 
DMA and TMA experiments, in serial or cyclic processes, pro-
vides a powerful approach [13][14]. These studies typically in-
volve many researchers with different backgrounds, each contrib-
uting to some steps of the entire process: biologists, chemists, 
pathologists, and clinicians. Their work is supported and com-
plementarily completed by physicians, computer scientists, 
mathematicians, etc., who are required not just to perform data 
analysis, but also to contribute to the management of whole ex-
perimental process from design to final data interpretation. 
As the throughput of this technology increases in the area of ex-
pression arrays, proteomics, and tissue microarrays, one of the 
critical issues is making sense of all this data. Therefore, the focus 
of this thesis is to develop a systematic approach to processing 
and bettering understanding data generated from one of these 
high-throughput discovery tools, the Tissue Microarray.  
TMAs can be used to examine multiple disease states, but this 
thesis will focus on its uses in the area of cancer, where most of 
the initial work has been. 
1.2. The Problem 
Tissue microarrays allow for high-throughput expression profil-
ing of tumor samples by evaluating potentially interesting candi-
Chapter 1  
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date genes and proteins, identified by other techniques, on a large 
number of well-characterized tumors.  
They can be used to investigate panels of molecules, trying to 
characterize solid tumor development or tumor progression. 
Moreover TMA studies have the potential to be translatable to a 
clinical application such as the development of diagnostic bio-
markers (e.g., AMACR [15]) or a potential to therapeutic target 
(e.g., Her-2-neu [16]).  
 
The TMA approach can be technically described as follows. It 
gathers into one paraffin block up to hundreds of minute tissue 
samples. Usually more than one sample from each patient is in-
cluded (sample replicate) to ensure tumor representativeness. 
Slices of this ‘block array’ are then analyzed by in situ methods 
on glass slides, evaluating DNA, RNA or protein targets, for iden-
tification of specific phenotypic (immunohistochemistry and in 
situ hybridization) or genotypic (fluorescence in situ hybridiza-
tion) alterations. Immunohistochemistry technique is most com-
monly performed, allowing the investigation of protein expres-
sion by analyzing the reaction of protein specific antibodies 
(biomarkers). 
 
The TMA technique is thus appropriate for population screening 
studies. The information you can get are best viewed on a popula-
tion basis and not on an individual patient basis. Thus the ques-
tion being asked is not if patient A, B, or C demonstrates expres-
sion of the biomarker in question, but instead, how often is this 
biomarker expressed in a population of individuals with a given 
disease state? Is this a commonly expressed gene? Is it expressed 
only rarely? Is it expressed only in patients who go on to have a 
worse outcome?  
 
In TMA experiments, as with all high throughput techniques, high 
quality experimental data production is extremely important for 
the reliability of data analysis. This critical issue needs to be ad-
dressed on two levels, i. critical assessment of experimental de-
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sign and organization and ii. reliability assessment of experimen-
tal data together with data preprocessing. In order to best deal 
with these two issues, a technological approach is advisable to 
properly manage data heterogeneity (biological, clinical and tech-
nical variables), data quantity and user diversity. This last aspect 
becomes even more crucial if data sharing occurs among and be-
tween research groups. Technological aspects may include auto-
mation to speed up data acquisition and evaluation that can be of 
great impact in overcoming TMA studies bottlenecks.  
Adequately tackling these problematic aspects is important to 
achieve good experimental results.  
A fundamental phase of each study is then data analysis. Standard 
statistical approaches and supervised and unsupervised learning 
algorithms have been successfully applicable to TMA preproc-
essed data in order to face prognostic predictive power assess-
ments, classification tasks or new class discovery tasks. However 
efforts are continuously done to better address peculiar necessities 
of these new types of data, by elaborating new dedicated methods 
for data analysis. For instance, some authors recently proposed 
approaches [17][18] to properly manage classification tasks when 
the target are continues data. This approach fits scenarios where 
the biological question is how can I characterize patients with 
good or poor prognosis equally histologically diag-
nosed/classified? Which is the profile that characterizes different 
clinical outcome data? Another issue that might be investigated 
regards the variability of measures in a classification problem. 
Standard approaches do not account for data uncertainty, which 
may be given by experimental multiple measures of protein levels 
on the same tumor (intra-tumor heterogeneity). Embedding this 
variability in classification models might add interesting informa-
tion to data analysis outputs. 
 
1.3. The Solution 
To appropriately exploit the high-throughput nature of the TMA 
technique, a comprehensive approach to data management must 
Chapter 1  
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be applied. Knowledge Discovery and Data Mining (KDDM) [19] 
processes provide an ideal framework for bioinformaticians to fit: 
from understanding the domain, forming a consolidated dataset 
from data sources, cleaning the data by selection and preprocess-
ing, extracting regularities in the data and formulating knowledge 
in the form of patterns and rules.  
The solution we propose here is a systematic approach to process-
ing and better understanding data generated in TMA based stud-
ies. 
Through a strong interdisciplinary approach, we tried to address 
all the issues related to this topic. In particular, we aimed to sup-
port both data collection from different users and data sharing 
across different institutions through a web based approach [20]. 
To support automation we employed digital pathology for acquir-
ing digital images of single tumor sample on a glass slide and as-
signing them to the donor tumor automatically [21] through im-
age processing and object recognition algorithms. Fully automatic 
evaluation of specific biomarker categories have been developed 
in order to avoid subjectivity problem and fully exploit the vari-
ability range of gene expression [22].However while full automa-
tion may be the Holy Grail in these experiments, currently careful 
supervision is still required to ensure that the samples are prop-
erly classified. 
This thesis addresses TMA data pre-processing issues, identifying 
critical points and some solutions. These models were tested on 
three TMA studies driven by different biological/clinical ques-
tions. The results of these three studies are presented in this the-
sis. 
We also focused on the specific issue of accounting for data un-
certainty in classification. We propose a novel classification 
model based on a Bayesian hierarchical approach. This model 
was tested on simulated data and on a real protein data set finding 
interesting differences, when compared to a standard Bayesian 
approach. 
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1.4. Innovative Aspects 
We present a new comprehensive system for the management of 
TMA experiment data (TMABoost) from tissue data collection to 
experiment design and gene expression evaluation. This system is 
able to handle a wide spectrum of studies and user requirements. 
This system integrates all the information related to TMA ex-
periments, regardless of experiment design, overcoming the limi-
tations of the systems that have been presented up to now.  
Our approach both reduces the possibility of errors and acceler-
ates the data analysis step on reliable data, particularly with re-
gards to the pre-processing phase. The system includes an image 
processing procedure and a robust algorithm for object recogni-
tion to automatically identify each tumor sample on the digital 
image of a TMA glass slide, assigning it to proper grid location, 
speeding up the acquisition of corresponding digital image by al-
most avoiding manual intervention. TMABoost allows data shar-
ing among institutions and is also able to face data exchangeabil-
ity needs [23]. An important aspect of our system is that, different 
from other academic systems or commercially proposed systems, 
it is patient based and not experiment based.  
Another innovative aspect we propose regards the treatment of 
uncertainty in the context of classification. The classification 
model is based on Bayesian hierarchical approach. It allows em-
bedding in the classification model the tumor intra-variability 
(heterogeneity of protein levels across tumor tissue), using the tu-
ple of protein level measurements of each case instead of unique 
representative value, as done by conventional approaches.  
 
1.5. Structure of the Thesis 
The second chapter of this thesis reviews the state of the art of 
TMA field with respect to data management and data analysis 
tasks. The third chapter introduces problems of performing mo-
lecular profiling at protein expression levels, from data handling 
point of view. Insights in TMA experimental technique and in situ 
Chapter 1  
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investigation methods are provided to illustrate TMA data 
sources. The chapters 4, 5, and 6 describe the TMABoost man-
agement system, the TMA data analysis steps with particular at-
tention to the preprocessing aspect, and the classification model 
we propose together with the performances we obtained. Chapter 
7 includes three examples of TMA based studies we conducted, 
focused on different biological questions. The chapter 8 summa-
rizes and discusses the problem and the proposed solutions and 
outlines on-going and future work on this topic. 
 
1.6. Notes 
Part of the work presented here has been granted by the Italian 
Ministry of Health (“Programmi speciali” – Art. 12 bis, comma 6, 
d.lgs. 229/99). 
During the three years training period I applied for a three months 
stage at the CHIP (Children’s Hospital Informatics Program, Bos-
ton, MA, http://www.chip.org/). During that period of time I col-
laborated with members of the Rubin laboratory (Mark A. Rubin, 
http://rubinlab.tch.harvard.edu/) at the Brigham and Women’s 
Hospital/ Dana Farber Harvard Cancer Center/ Harvard Medical 
School in Boston, being involved in TMA experiments for the 
study of prostate cancer progression. This work was funded by 
the National Cancer Institute of the NIH (U.S.A.) Prostate Cancer 
S.P.O.R.E. program. 
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2. State of the Art 
 
To facilitate the in situ investigation of molecular markers in tu-
mor samples, the tissue microarray (TMA) technique was recently 
developed [12]. TMA technology allows researchers to assemble 
hundreds of tumor samples into a single paraffin block. Sampling 
has been a major concern regarding TMA technology. How well 
do tissue samples, often with a diameter of 0.6mm, represent the 
entire tumor? Many of the initial TMA studies addressed this is-
sue, by estimating the number of core replicates necessary and 
sufficient to achieve same results that would be obtained with 
conventional glass slides [24]. Another approach is to estimate 
the number of required cores to have evidence of well known as-
sociation of a protein with some histological or clinical variables 
[25][26]. Some authors [27] also report that the sampling issue 
can be ignored and one core for each patient is sufficient for al-
most all TMA based study purposes. These different approaches 
suggest that there is no unique answer to the question of sam-
pling. Perhaps the most critical deciding factor depends on tissue 
homogeneity and biomarker characteristic. 
There have been also some attempts to formally compare the con-
sistency of TMA analysis from one center to another. However, 
only a few of these have been published to date [28]. 
 
In the last few years an increasing number of studies has been 
published based on TMA technique, mostly aimed to investigate 
single protein expressions [29] to assess diagnostic or prognostic 
marker capability. TMA have recently been used to analyze pan-
els of proteins trying to characterize specific disease molecular 
profiles [9].  
Chapter 2  
12 
 
Even more recently, TMA based investigations are included in 
cross platform approaches [30][31]. 
The focus of this chapter is not to review all of the biologic stud-
ies associated with TMA, but rather to focus on those research 
studies aimed at managing TMA data with respect to data collec-
tion, data organization, data analysis and data sharing. 
 
In the setting of high throughput experiments where considerable 
amounts of heterogeneous data are present and many parameters 
are involved, the lack of appropriate tools to handle experiments 
and data represents an important problem for the future of the 
TMA field with respect to data interpretations. Moreover, inte-
grated and comprehensive solutions would work for emerging 
studies, which could share previously studied cohorts or could in-
clude previous detected information and knowledge, taking ad-
vantage of well organized databases. 
Another important feature of TMA based studies is the growing 
need to share data and information among different institutions 
(e.g., multi-center studies, clinical trials, etc.). In such a setting, 
the implementation of standard data exchange protocols becomes 
critical as up to now there have not been standard approaches to 
collecting data at different institutions and sometimes even within 
the same institution and as centralized solutions are not feasible. 
As a result of several TMA workshops in the area of TMA bioin-
formatics, some authors have reported [23] on a community-
based, open source tool for sharing tissue microarray data; the ex-
change specification approach is based on a well-formed XML 
document. Others [32] proposed a specification of semantic meta-
data schematics for TMA in a peer-to-peer infrastructure design.  
 
As for data handling, the use of a large spreadsheet has been the 
standard solution. This approach is useful for experiments on a 
one-time basis, but becomes very cumbersome when analyzing 
multiple markers on a given specimen or when having multiple 
observers render diagnoses and scores on a given specimen [33]. 
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A grid sheet for scoring and analysis and a spreadsheet containing 
the list, type and position of each tissue core are, for example, 
provided by the Tissue Array Research Program. It is a collabora-
tive effort between The National Cancer Institute and The Na-
tional Human Genome Research Institute 
(http://ccr.nci.nih.gov/tech_initiatives/tarp/), which primary ob-
jective is to develop and disseminate Multi-Tumor Tissue Mi-
croarray slides and the related technology to the cancer research 
investigators. 
 
Few papers have been published so far on TMA data organization 
and management. Liu et al. [34] presented a system for high-
throughput analysis and storage of TMA immuno-staining data, 
using a combination of commercially available software and 
novel software. Similarly, Shaknovich et al. [35] proposed a way 
to manipulate TMA data and images, using commercially avail-
able software. Manley et al. [36] highlighted the peculiarities re-
lated to high density information glass slides, providing a source 
of inconsistency between tissue core sections and donor blocks 
identifiers. They proposed the used of a relational database for the 
better organization of TMA data. A validation study of the proto-
type system was then published [28]. 
Recently a web-based prototype for imaging, analyzing and ar-
chiving TMAs was proposed [37], mostly focusing on automatic 
evaluation of biomarkers. It also faces the problem of automati-
cally extract single tissue locations to allow unsupervised regis-
tration of arrays, proposing an approach which works well with 
rigid rotations of the core section array on the glass slide. 
Academic groups are working on the development of systems in-
tegrating commercially available software for the acquisition of 
digital images and the automatic evaluation of markers with cus-
tom solutions of data organization and management.  
For instance, the TMA Profiler system developed in Rubin labo-
ratory (http://rubinlab.tch.harvard.edu/htma/profiler/index.jsp) in-
tegrates the Chromavision system outputs (Chromavision Medical 
Systems, Inc., San Juan Capistrano, CA. Automated Cellular Im-
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aging System (ACIS II)) in a web based platform to handle TMA 
experiment data (see additional data in [92]). 
Similarly the Johns Hopkins TMA Laboratory, 
(http://tmalab.jhmi.edu/) employs an open source software (for 
academic use) to manage a TMA Database, TMAJ [38]. It allows 
the storage of a wide variety of information related to TMA sam-
ples, including patient clinical data, specimens, donor blocks, 
core, and recipient block information. A dynamic database struc-
ture allows users to add custom fields for different organ systems. 
The client application facilitates automated and manual entry of 
data related to patients, specimens, tissue blocks, and tissue sub-
blocks (individual pathological diagnoses). The system allows us-
ers to design their own. Digital images generated by the Bacus 
Labs Inc. Slide Scanner (BacusTM laboratories, Lombard, IL, 
http://www.bacuslabs.com/) are imported into the database and 
available for on line visualization and evaluation.  
The AQUA system [57] uses a custom imaging microscope sys-
tem for scanning TMA slides stained with fluorescent markers. It 
uses an object recognition approach to exactly identify the spatial 
coordinate of each spot, but lacks in ordering and assigning them 
to proper patient and/or clinical information based on construc-
tion information.  
Some other systems aimed to automatically acquire and evaluate 
TMA samples are available, such as the TMALab ™ (Aperio te-
chnology, http://www.aperio.com) or the Pathfinder
TM 
Morpho-
scan™ (http://www.imstar.fr/). 
These solutions are appropriate to handle very good quality TMA 
slides, usually by superimposing a grid on the panoramic over-
view of the slide, but they require considerable manual interven-
tion if the samples are distorted (for instance, asking the user to fit 
the edge of each grid cell appropriately in case of misalignments). 
 
With respect to data processing, usually conventional approaches 
are taken in handling TMA data. The most common approaches 
are statistical and machine learning ones. Some TMA studies 
have attempted to address a few issues related to data analysis 
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(see chapter 5) such as dealing with dichotomization protein ex-
pression levels and pooling data from replicate tumor samples 
[39][40]. 
Usually replicate tumor samples are included in TMA dataset in 
order to account for tissue heterogeneity. The pooling of protein 
level measurements detected on replicate samples is commonly 
straightforward adopted, therefore neglecting part of the informa-
tion. An approach to model data uncertainty is proposed by Bhat-
tacharyya1 et al. [41]; they include the data uncertainty in classi-
fication and relevant feature identification algorithms based on 
robust sparse hyperplanes, by associating each data point with an 
ellipsoid parameterized by a center and covariance matrix. A dif-
ferent approach in handling the data uncertainty may regard the 
use of multilevel models (or hierarchical models) [42][43], suit-
able to analyze information available at different levels of obser-
vation units (as for example, in meta-analysis of separate random-
ized trials).  
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3. Molecular profiling at protein expres-
sion 
3.1. Scenario 
Gene expression is the process by which genomic information is 
converted into the structures and functions of a cell, by producing 
proteins from DNA coding sequences (see Figure 2). Genomic 
expression is more and more under investigation, trying to depict 
molecular profiles characterizing specific disease states. New 
technologies, microarrays, allow tracking the translation of ge-
nome sequences into gene functions (functional genomics), lead-
ing to the identification of highly informative genes and pathways 
with potential impact on understanding disease development and 
progression [44], concurring to improve diagnostic and treatment 
modalities and to detect targets for new therapies [45]. Despite 
different kinds of investigation, all microarrays generate large 
datasets by simultaneous detections under the same experimental 
conditions. In particular DNA microarrays (DMAs) analyze 
mRNA expression, and Tissue microarrays (TMAs) evaluate 
DNA, RNA or protein targets through in situ investigations 
(analyses performed on tissues).  
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Figure 2 - Gene expression (Picture taken from National Human 
Genome Research Institute (2001)). [Gene expression is the process 
by which a gene's information is converted into the structures and 
functions of a cell. Gene expression is a multi-step process that be-
gins with transcription and translation and is followed by folding, 
post-translational modification and targeting. The amount of pro-
tein that a cell expresses depends on the tissue, the developmental 
stage of the organism and the metabolic or physiologic state of the 
cell.] 
Microarray technology is extremely powerful because of the 
high-throughput nature of the approach, giving great advantages 
with regards to experimental execution time and experimental 
homogeneity, both being particular relevant for comparative stud-
ies. 
In molecular profiling studies of human cancer, integration of 
DMA and TMA experiments provides a powerful approach; 
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genes selected by DMA studies can then be simultaneously inves-
tigated by pathologists on large set of well characterized solid 
tumors by immuno-histochemical or nucleic acid hybridization 
techniques. 
3.2. Data management problem 
How can we make sense of all the data produced by these high 
throughput technologies? How can we be sure that our data are 
of good quality and therefore that data analysis results are reli-
able?  
Common critical points of these new experimental techniques are 
data control and data quality, which should be account from the 
assessment of experimental data production and collection to data 
interpretation.  
In TMA studies, data collection and organization are extremely 
relevant: heterogeneous data types are included in studies (gene 
expression levels, histopathological data, clinical data), several 
data sources are involved and the evaluation procedure of gene 
expression levels on TMA samples is definitely prone to error 
[45], as for instance association errors in designing the block ar-
ray or evaluating a slide may easily occur.  
Efficient retrieval of data is also desirable, both as TMA studies 
are usually based on several single experiments on the same co-
hort of patients and for new experiment design. Data and informa-
tion sharing is also mandatory as often multi-center studies are 
performed.  
Components to be considered in this context are thus i. critical as-
sessment of experimental design and organization, ii. reliability 
assessment of experimental data and iii. technological support to 
organize and collect data, also implementing automation. 
 
As far as data organization is assessed the problem shifts to data 
analysis and interpretation. Even if a lot of work has been done on 
gene expression data analysis and traditional approaches might be 
successfully applied very often, the TMA data analysis phase is 
not trivial. Great attention in preprocessing phase should be 
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adopted; appropriate analysis approach must be carried out de-
pending on specific biological or clinical question. (i.e. hypothe-
sis driven studies). 
 
Even if technical support is provided and automation is employed 
to speed up the experimental process, a very important step is 
data preprocessing. Contrarily to what happens on cDNA mi-
croarrays where single elements are processed, tissue samples are 
part of solid tissue, thus being spatially heterogeneous. Every 
TMA glass sample, even if consecutively obtained, contains 
slightly different tissues (see section 5.3.1).  
Another kind of heterogeneity is addressed by intra-tumor hetero-
geneity: protein expression may vary across the tumor. Multiple 
measures of protein expression on the same tumor must be han-
dled during data analysis. The latter is a problem that is usually 
skipped in TMA data analysis, as conventional statistical and ma-
chine learning approaches do not account for data uncertainty. 
 
To efficiently and practically face the above mentioned problems 
a strong interdisciplinary effort must be done. Accurate attention 
must be given to all the aspects concerning this experimental 
technique and its possible integration with experimental data ob-
tained with other platforms. 
Knowledge Discovery and Data Mining (KDDM) [46][47][48] 
processes provide an ideal framework for bioinformaticians to fit: 
from understanding the domain, forming a consolidated dataset 
from data sources, cleaning the data by selection and preprocess-
ing, extracting regularities in the data and formulating knowledge 
in the form of patterns and rules.  
 
Lack of integration and uncontrolled data collection activities not 
only affect study results, but also damage future activities sharing 
same patient or same data or protocols, which could have taken 
advantages of all previous work. 
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The next session describes TMA techniques with particular em-
phasis on common problems that can affect experimental condi-
tions. 
3.3. Tissue Microarray Technique  
 
The first attempt to increase the throughput in terms of number of 
samples for simultaneous in situ analysis was proposed by Batti-
fora [49] in 1986 with the ‘tissue sausage’ technique. The intent 
of this “tissue sausage” was to increase throughput in the evalua-
tion of antibody staining properties for a variety of tissue types. 
The Tissue Microarray [12] technique improved on the haphazard 
arrangement of the tissue samples and by placing the samples in 
an ordered array allows for high-throughput in situ experiments 
using immunohistochemistry, FISH, or in situ hybridization. The 
TMA approach has a dramatic advantage over the conventional 
approach in performing in situ experiments on standard glass 
slides. The standard approach requires performing many experi-
ments on separate slides with the major drawback of inter-
experimental differences due to variability of staining from one 
slide to the next and an inefficient use of tissue samples. The 
TMA approach allows for the simultaneous staining of hundreds 
of tissue samples from as many patients. Thus this TMA approach 
is a high throughput process, which ensures experimental stan-
dardization across all patient samples (i.e., all tissue samples are 
pre-treated and treated under identical conditions). Perhaps one of 
the most critical advantages is that TMA technologies conserve 
the limited tissue resource, which is vital given the increasing 
number of candidate genes that need to be explored. 
The TMA technique is demonstrated in schematic form in Figure 
3. Tissues are arranged in a pre-ordered matrix. Cylindrical tissue 
biopsies are transferred with a biopsy needle from carefully se-
lected morphologically representative areas of original paraffin 
blocks (donor blocks). A hematoxylin and eosin (HE) stained sec-
tion of the donor block is usually aligned to better locate the rep-
resentative areas. Core tissue biopsies are then arrayed into a new 
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“recipient” paraffin block by using a manual or an automated tis-
sue arrayer (e.g. Manual Arrayer, Manual Arrayer, Beecher In-
struments Inc, Sun Prairie, WI, USA), using a precise spacing 
pattern along x and y axis, which generates a regular matrix of 
cores. TMA topology design is not unique and may vary depend-
ing on the study design, number of tissue cores, and the types of 
potential experiments. 
 
A TMA block (block array) can theoretically contain over 1000 
cores but for practical reasons, most experts in the field do not 
place more than 600 hundred tissue biopsies on a single block. 
The number of samples may also vary depending on the needle 
diameter used to transfer the samples (from 0.6 to 2 mm in diame-
ter) [12][45]. TMA sections are serially obtained at 4-5 microme-
ters thickness [50] with a microtome, a precision instrument de-
signed to cut uniformly thin sections of materials for microscopic 
examination purposes. About 150 sections can typically be ob-
tained from one block array. However, the number of sections 
will ultimately depend on the depth of the tissues originally 
placed into the recipient block. [51]. Construction of identical 
TMA blocks (settled up with the same donor materials and in the 
same order) is also common, to further scale up the method. 
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Figure 3 - Tissue Microarray Technique scheme. 
 
Sampling is always a concern in the field of pathology. Rarely do 
pathologists review an entire organ but instead take representative 
samples. TMA technology is no exception to this common prac-
tice. How well these tissue samples, often as small as 0.6 mm in 
diameter, represent of entire tumors has been the focus of several 
recent studies [52][53][54]. Some authors [55] also report that be-
cause TMAs are mostly intended for population level screening 
tool than for diagnoses on individual cases, this aspect is not criti-
cal. The results of those studies are dependant on tumor types and 
study purposes. A biomarker with homogenous expression 
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throughout the entire tumor will not require as many samples as a 
biomarker that is only focally expressed by the target tissue. In 
order to capture some of the intra-tumor heterogeneity, multiple 
cores are often taken from each donor block and arranged in the 
same block array. 
3.3.1 Common problems with TMA section preparation 
During the preparation of TMA slides, due to technical problems 
the content and/or the perfect alignment of the array may be al-
tered. For example, as the donor tissues may not all have the same 
depth, as one cuts deeper into the TMA, some individual TMA 
cores will disappear due to the absence of that particular tissue 
core (i.e., exhausted tissue). Core sections may be fragmented 
during the cutting process with even the most sensitive micro-
tome. The transfer of the TMA section from the microtome onto 
the glass slide may also lead to tissue loss. Through imprecise 
processing, the array may be distorted and one or more rows 
and/or columns may be bent, folded or moved from their original 
position (see Figure 14).  
 
To reduce the array distortion and bending problems, the TMA 
sections may be placed on the slides using a tape transferring sys-
tem (Instrumedics, Hackensack, NJ). With this system the sec-
tions are captured flat and uncompressed on a tape-window as 
they are cut and then transferred to an adhesive coated slide. This 
procedure, adopted by many laboratories, requires altering 
slightly the staining protocol. The tape system reduces distortions 
and bending problems, but, with varying degrees of frequency, 
misalignments are almost always present even on the highest 
quality TMA samples. 
 
Due to tissue heterogeneity, the original targeted tissue placed 
into the TMA may appear different as one goes deeper into the 
TMA block. This is expected given the 3 dimensional nature of 
the samples being used. This limitation requires that the samples 
be evaluated repeatedly at all layers. 
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3.3.2 In situ investigation  
All in situ experiments that can be performed on standard tissue 
sections can also be performed using TMAs. The TMA approach 
has the added advantage, however, of being able to increase 
throughput and limit experimental variability often encountered 
with standard slides. TMAs can be used to detect DNA, RNA or 
protein expression, by using in situ hybridization or immunohis-
tochemistry[56].These methods do not alter the tissue morphol-
ogy and therefore information on distribution of the expression 
within the tissue can be obtained at the level of individual cells, 
even in cases where the expression occurs only in a few cells. 
One major advantage of examining expression in situ is the abil-
ity to determine the exact location of expression down to sub-
cellular level. For example, expression of a biomarker such as 
beta-catinin in colorectal cancer has a dramatically different 
meaning whether it is expressed in the cell membrane (inactive 
form) or in the nucleus (active form) [57]. Expression detection 
and localization concur to potentially interesting information.  
 
The expression evaluations of these in situ tests have been tradi-
tionally performed by pathologists using microscopy (either 
bright or dark field). For example, immunohistochemical experi-
ments are often evaluated by pathologist for staining intensity us-
ing a four nominal point scale (negative, weak positive, moderate 
positive, strong positive), and the percentage of the stained area. 
However, the human eye, even if trained, cannot detect subtle dif-
ferences in staining intensity on a continuous scale, in particular 
at very low and very high levels of the scale. Moreover it is well 
known that nominal categories are subjective and inter- intra-
observer agreement is usually poor. In contrast, automatic detec-
tion of immunostaining provides continuous quantitative meas-
ures, also ensuring reproducibility due to objectiveness of the 
measurements (see chapter 5.2). More recent work in the field of 
TMA biomarker development has focused on the use of semi- or 
fully-automated image processing. The continuous quantitative 
measurements obtained by automatic evaluation can better detect 
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the information of the investigated target, allowing the detection 
of subsets of tumors not seen using human/pathologist based as-
sessments as demonstrated in [57], where fluorescent probes were 
used. 
 
3.3.2.1. Immunohistochemistry 
Immunohistochemistry is the process of detecting protein expres-
sion in situ using antibodies targeted at the protein of interest. The 
antibodies used can be polyclonal or monoclonal in origin, the 
monoclonal ones being more specific in nature. Immunohisto-
chemistry is widely used in the evaluation and diagnosis of can-
cers and other disease states. Therefore, most practicing patholo-
gists are familiar with this technique. Regardless their source 
(monoclonal, polyclonal or recombinant) not all antibodies work 
equally well. Specificity, sensitivity and antigen preservation 
must be considered [56]. False positives can be due to cross-
reactivity with related or unrelated epitopes. False negatives can 
arise when the antibody fails to recognize the epitope within the 
tissue, the epitope was altered by fixation, the epitope is present at 
too low level or it is inaccessible for the antibody due to other 
reasons (protein-protein interactions, cross-linking or modifica-
tion).  
 
Pre-processing technique may also play an important role in the 
performance of these in situ techniques. Tissues are routinely 
placed into a fixative such as a 10% formalin solution. After a 
variable time in this fixative, the samples are embedded in paraf-
fin blocks. This procedure is used to preserve tissue morphology 
and stabilizing the tissue from degradation, but a drawback is that 
it can modify target antigens. For routine purposes, probably 99% 
of all processed tissues reside in this state. An alternative, most 
often associated with research protocols or molecular analysis, is 
the procedure where samples are snap frozen requiring no fixative 
such as formalin. Research investigators are developing arrayers 
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capable of handling frozen tissue samples instead of paraffin-
embedded ones [39][58]. 
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4. The TMA data management system 
 
Before construction of our TMA management system, we took 
into consideration some of the critical issues related to the stan-
dard needs and requirements of TMA experiments: 
- TMA studies may often involve considerable numbers 
of patients, heterogeneous data are involved, and different 
kind of users interacts at different times. Users are often 
from different institutions; 
- TMA technology is prone to several common types of 
errors: association errors in designing the block array or 
evaluating a slide may easily occur; 
- Patients included in a TMA study (included in one block 
array) might be later on included in some other TMA 
studies or tissue based studies. (One to many type of rela-
tionships need to be considered).  
 
These observations led us to develop a system with the following 
features: 
i. patient centered and not experiment centered,  
ii. work flow oriented accounting for all phases of TMA 
experiments (patient data collection, design experiment, 
data production),  
iii. optimal level of automation, 
iv. web based to allow for easy access and strong inter-
institutional capabilities. 
Based on these guidelines we constructed a system, where me-
dium-long term advantages are data sharing, data quality en-
hancement and data reusability. We paid attention to balance 
flexibility requirements and constraints in user interface imple-
mentations, in accounting for the storage of all the details that 
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make an experiment reproducible (for ex. staining preparation 
protocols, digital image acquisition setting as lamp intensity, fil-
ters) and speeding up data acquisition and evaluations implement-
ing automation.  
4.1. User Requirements, Need Assessment and System 
Development 
Need assessment and user requirements have been defined, col-
lected and analyzed from the very beginning of the work/project. 
We conducted face-to-face interviews with the different potential 
system users, focusing on workflow definitions and working con-
straints. 
We took advantage of an already available common working lan-
guage between the potential system users and our group, due to 
previous collaborations. The main potential users of the system 
are pathologists, biologists, laboratory technicians and clinicians. 
Modifications of system features were adopted not only during 
the course of the system design phase but also during the imple-
mentation phase and test phase, consistently with generic life cy-
cle models [59]. 
We implemented a first prototype running in local environment. 
During a four month period of usage, we collected comments and 
observations on data flow and interface acceptance. Modifications 
were then implemented in the web version of the system. 
 
4.2. TMABoost System 
The TMABoost system [60] consists of i. a web based application 
to collect all data involved in TMA studies: patient and tumor 
data, donor block information, block array information, array 
slide staining, core section evaluations, etc., ii. a relational data-
base to store the data and iii. a digital TMA environment based on 
the usage of a robotic microscope and image processing algo-
rithms to exploit digital pathology [61][62]. This environment 
automatically acquires glass slide overview images and single 
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core section images. Images are stored in the database and can be 
visualized by pathologists through the web interface. Moreover, 
automatic quantification of biomarker expression can be com-
puted on these digital images, avoiding subjectivity in human 
evaluation and allowing novel associations thanks to the continu-
ous nature of produced data.  
The choice of developing a web-based system was driven by dif-
ferent motivations. First, a web-based system facilitates the col-
lection of data from several institutions, providing access from 
virtually everywhere with an Internet connection. As studies be-
tween multi-centers is becoming more and more common, this 
system needed to be capable of gathering material, information 
and clinical data for specific research purposes from multiple 
sites. This web-based system also allows pathologists from these 
different institutions to evaluate the same TMA images. 
 
In the following sections the system will be presented in terms of 
system architecture and system components separately. This al-
lows describing more intuitively system functionalities, data in-
put, data retrieval and automated data collection. In particular we 
describe i. the system core, composed by a relational database, a 
middle/processing layer, and a web browser interface, and ii. the 
Digital TMA Environment. 
 
4.2.1 System Architecture 
Due to the functional requirements the general architecture of the 
system has been designed following standard web-based 3-tiers 
architecture [59]. 
System modules are logically grouped into three layers (see 
Figure 4) for which a brief description is here reported. 
The presentation layer is the representation of the system state to 
the user. It is made of two modules: the web browser and the 
Digital TMA Environment. Web pages are mostly Dynamic Hy-
per Text Markup Language (HTML) pages. We used Javascript 
language to provide several controls on user data entry. For pages 
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that require a lot of data entry, we used eXtended Markup Lan-
guage (XML), together with Microsoft XML DOM, both to or-
ganize and represent the information. This solution, coupled with 
Javascript code, allows performing some computation on the cli-
ent side, reducing server workload and client/server communica-
tion. We used Microsoft Internet Explorer 6.0 as web browser. 
The Digital TMA Environment interacts with the database 
through the Web System Communication Module (see Figure 11). 
This module establishes a connection with the web server to re-
trieve relevant information from the database: the block array 
map and the block array construction parameters, information re-
quired for the object recognition procedure. Moreover, the Web 
System Communication Module returns to the server both the ac-
quired digital images and the results of the automatic biomarker 
evaluation. Digital images are sent as an independent background 
process. This allows the user to perform other tasks, while trans-
ferring the images. The overall activities of this module are per-
formed seamlessly to the user. 
 
The middle layer is made up by the web server; we used Micro-
soft Internet Information Server 5.0. We employed Active Server 
Page (ASP) and Vbscript/Javascript on the server side to allow 
and control the communication between the user and the data-
base. In addition the source code of the middle layer is written on 
a central server and thus system upgrades and improvements are 
easily performed and immediately available to all users. 
A Secure Socket Layer (SSL) has been established to ensure data 
encryption between the client (user workstation) and the server, 
preserving security and confidentiality of communications. More-
over, authentication of the user is based on login and password 
that, thanks to SSL, are properly transferred to the central web 
server in a secure way. 
 
The Digital TMA Environment can send images to the middle 
layer through standard HTTPS protocol. The middle layer then 
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stores them into the proper table of the database as Binary Large 
Objects (BLOB).  
In the data layer we employed a relational database (Microsoft 
SQL Server) to store the data. SQL server is a XML enabled 
Database management System (DBMS) [63]. The database is im-
plemented behind a firewall. 
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Figure 4 - Web-based 3-tiers architecture of TMABoost system. 
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4.2.2 System Components 
4.2.2.1. System Core: the database 
 
A relational database [64][65] addresses data organization re-
quirements in an efficient manner, enabling data consistency, cor-
rectness, and completeness. Unique identifiers - automatically 
computed by the database engine - are used to link records be-
tween different tables, giving considerable advantages in terms of 
performance. This solution allows avoiding inconsistencies in the 
data and, together with the middle layer, reduces possible errors 
in linking biological/genetic, pathological, and clinical informa-
tion. The database management system we employed is Micro-
scoft SQL Server 2000. 
The relation diagram of the main tables is shown in Figure 5. 
Tables can be grouped as i. patient and tumor content tables 
(tb_paziente, tb_tumore_paz, tb_tu_metastasi, tb_tu_recidiva, 
tb_donor_block), ii. TMA experiment preparation tables 
(tb_block_array, tb_block_array_map, tb_array_slide, 
tb_core_section, tb_acquisizione_slide, tb_images) and iii. TMA 
experiment data tables (tb_valut_man_core_section, 
tb_valut_auto_core_section, tb_images_analysis).  
In addition, there are nine auxiliary tables, mostly of them inde-
pendent from TMA technique, containing system user informa-
tion, tissue provenience information, histology classification, 
biomarker descriptions, laboratory protocol codes for block array 
and slides preparation, etc.. 
 
A one-to-many relation between the tumor table and the donor 
block table does not allow inserting donor block information, us-
able for a TMA block design, without previously inserted tumour 
data. 
Similarly, it is worth noting the relation between the donor block 
table and the block array map table: it ensures consistency be-
tween tumour/patient data and the cores of the block array. This 
relation is crucial, as an error in the block array map propagates 
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along all experiments based on that block. The block array map is 
unique for each block array and every successive data related to 
one TMA glass slide relies on the map.  
 
The system allows each core section be evaluated multiple times, 
both by humans (tb_valut_man_core_section) and by automatic 
procedures (tb_valut_auto_core_section). The one-to-many rela-
tion between the array slide table and the acquisition slide table 
accounts for multiple acquisitions of the same TMA slide, for in-
stance under different wavelength filter conditions, different lamp 
intensities, different field filters, etc.. 
 
Individual patient identifiers are not included in the database, 
which contains only de-identified data [48]. The system automati-
cally assigns a unique code to each patient.  
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Figure 5 – Relational diagram of the TMABoost database. 
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Database Roles/User profiles 
The DBMS manages user authentications by Login and Password. 
The DBMS also manages user roles. Seven profiles have been de-
fined, granting role-based access to system data; each profile dif-
ferently allows operations on table records as select, insert, up-
date, and delete.  
Each user is associated to one or more profile.  
The defined profiles are the following: technician, clinician, 
evaluator, pathologist, automatic evaluator, administrator, demon-
stration user.  
All the profiles have been granted read access to the database ta-
bles and, with exception of the administrator, none can delete re-
cords. 
The technician role has write access on the tables concerning the 
donor block preparation, the preparation of the block arrays, the 
maps, and the staining of the glass slides. The clinician role has 
write access to the tables concerning the patient and the tumour. 
The evaluator role can insert data only in the core section evalua-
tion table. The pathologist role has the broadest entry access to 
the database: it embraces all the permissions of previous users.  
The automatic evaluator profile is the one used by the Digital 
TMA Environment to access the database: it can insert data in the 
core section table and in the automatic evaluation table.  
The demo user profile has been added to allow potential new us-
ers to navigate into the system for a finite time period. The mid-
dle/processing layer grants their access to a test version of the da-
tabase. 
Constraints to handle data ownership are not yet implemented. 
They will turn out to be useful to allow individual research group 
to share or separate their data, based on study and sample permis-
sions. These permissions can in turn be used to securely limit ac-
cess to specific specimens, blocks, array-blocks, and sessions.  
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Database Triggers 
SQL Server supports using triggers as a kind of stored procedure. 
Triggers are commonly executed when a specified data modifica-
tion (for instance an attempt to delete a row) is attempted on the 
table on which the trigger is defined. We implemented some trig-
gers to seamlessly perform control or updating operations on data. 
For instance, any change in patient’s clinical data, such as status 
(alive with relapse, alive without relapse, dead for disease, dead 
for other causes), last follow up date, etc., automatically updates 
related information for survival analysis studies. Triggers can, on 
demand, be implemented on additional fields to address different 
endpoints. For instance, PSA failure in prostate cancer might have 
multiple definitions.  
The usage of triggers is relevant, since clinical information can be 
repeatedly updated by different users.  
 
4.2.2.2. System Core: the middle/processing layer 
Besides allowing the communication between the user and the da-
tabase, the middle/processing layer performs several processing 
steps to control data workflow. It provides the user with the 
proper interfaces for collecting and retrieving data, as better de-
scribed in the following sections. Moreover, it controls user input 
performing a first filtering level on inserted data. 
It also handles the communication with the database, by saving 
and requesting data. A fundamental aspect performed by the mid-
dle/processing layer is mapping the relational structure of the da-
tabase into a hierarchical one by using eXtended Markup Lan-
guage (XML). This solution allows exchanging data back and 
forth between the client and the server in a more efficient manner, 
reducing communication workload, and performing part of the 
computation on the client side. For instance, when the user is 
evaluating a slide, all core section information is downloaded 
once from the database as a XML structure. When the user selects 
a certain core section, only the corresponding data are shown 
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through JavaScript code executed at client side (see Figure 6). 
The user then inserts or modifies core section evaluations through 
the HTML interface. Seamlessly to the users, these changes up-
date the XML structure on the client side, by JavaScript code. 
Only when data are completely inserted or upon specific user re-
quest the XML structure is sent back to the web server. The mid-
dle/processing layer then processes the XML structure and ex-
tracts the data in a suitable format to update the database.  
Same approach can be implemented to extract data accordingly to 
every XML predefined structure, as the one proposed by [23] to 
exchange TMA data. 
A key point of the middle/processing layer is the communication 
with the Digital TMA Environment (see Section 4.2.2.4). In par-
ticular, the exchanged information regards array slides and block 
array maps, automatic biomarker evaluation data, and digital im-
ages. 
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Figure 6 – XML extract: single spot description data and staining 
evaluation data. 
4.2.2.3. System Core: the web browser interface 
 
Particular attention has been given to the user interface design, 
addressing different needs of different users that operate in dis-
tinct work phases; workflow needs, differentiated for input and 
retrieval phases have been considered.  
The web system interface is divided in to two frames: a naviga-
tion frame and a main frame. The navigation frame (see left frame 
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in Figure 7) allows the user to select different levels of informa-
tion, as patient identification number, tumor and donor block 
data, block array or array slide data. For each group of informa-
tion, inserting and retrieving pages are available in the main 
frame. Searching and retrieving data can be done through inter-
faces that present the user with predefined criteria for specific 
queries (dynamic queries). Results are then reported as lists of tu-
ples, sorted as requested. Result lists can be used to further navi-
gate in to the system. 
 
Different types of constraints are made on web interface level to 
increase data reliability. Constraints on most of the data insertion 
fields are employed. Controls on data type entries (date, string, 
numbers) are present, control boxes for list choices are imple-
mented as far as possible (pick up tables). In some cases the list 
items depend on other selection. For example, during tumor data 
insertion as the organ is selected, the appropriate lists for T, N 
and M (Tumor-Node-Metastasis classification) are loaded.  
Accordingly to database constraints, some data fields are compul-
sory (controls made when the user tries to save, before sending 
the data to the database) and some others allow for data entry 
only accordingly to database contents. The latter case occurs for 
the block array map insertion: to insert data of each new punch, a 
list with all the available donor block codes is presented to the 
user. 
 
One specific example of data insertion capability would be how 
the system helps guide the technician/user through the design 
phase of virtually constructing a TMA. This procedure is care-
fully defined i. to allow the user to select donor blocks to be asso-
ciated to each cell from a list (no typing allowed), ii. to force the 
user to the pre-declared structure of the block array. To further 
help the technicians in the insertion phase of the block array map, 
some tools were implemented, such as an additional button to 
automatically insert data of multiple biopsies from the same do-
nor block without reselecting it from the list and a graphical solu-
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tion based on differentially colored map cells to visually identify 
such replicates (see Figure 7). This structure is highly preferred 
because block array map insertion is definitely prone to error. 
Eventually information about cuts/slices of each block array can 
be stored in the system at any time. At each new cut of a block 
array the system automatically assigns a label to it, composed by 
the code of the block array and an incremental number.  
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Figure 7 – Screenshot of TMABoost: block array map data entry. 
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Figure 8 – Screenshot of TMABoost. Information of single block ar-
ray made of 10 rows and 18 columns; preparation data and map of 
a block array is represented: as the mouse is moved over the map 
cells, data of the selected core appears on the top of the map. 
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Another example of the web interface is given in Figure 9. It 
shows the system interface for the input and the retrieval of bio-
marker evaluation of a single glass slide. Mouse clicks or shortcut 
keys can be used to move across the slide map, which is auto-
matically prepared on the basis of corresponding block array 
stores data. In the top frame two types of information related to 
the selected core section are shown, i. data of the donor block 
where the core section comes from (tissue type, diagnosis), and ii. 
core section evaluation data (possible evaluation of the spot, di-
agnosis confirmation, biomarker evaluation data). The user may 
decide to visualize single core section images during slide evalua-
tion or visualization, moving from one core section to another. 
Shortcut keys have been implemented to ensure fast data inser-
tion.  
Multiple evaluations of the same TMA slide are feasible and each 
is designated as a separate session. Each user (associated to the 
evaluator or pathologist profile) can edit only its own evaluations. 
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Figure 9 - Biomarker evaluation: TMABoost interface; the upper 
window shows the image of the selected core section. 
 
4.2.2.4. Digital TMA Environment/ TMA Acquisition Environ-
ment 
To ensure comprehensive information storage and large scale 
analysis, digital images of glass slides and of single core section 
must be acquired and stored. 
The storage of digital images of each core section has two main 
advantages: 
- it makes tissues available to pathologists involved in 
specific studies through the web, enabling on screen 
core section evaluation or review; 
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- it allows the automatic evaluation of gene and pro-
tein expression through image processing routines, 
avoiding subjectivity (see Figure 12). 
Provided digital images are almost mandatory at least to offer 
complete information storing of TMA experiments, an efficient 
solution must be found to speed up this phase. 
In addition, future changes in editorial policy may require submit-
ting all images associated with TMA studies at time of review and 
publication, as is common practice with expression array studies. 
 
A key point of the present system is given by the integration of an 
automated digital TMA acquisition system, ‘connected’ to the 
TMA database through the web server.  
 
The TMA acquisition system employs a robotic microscope, 
which is a microscope drivable by software in each movement: 
stage movement on x and y axes, magnification change, z-axis 
movement, auto focus, etc. Robotic microscopes are largely used 
for telepathology applications, for the creation of digital slides 
(entire histological or cytological specimens) for several purposes 
[62] and recently for the acquisition of TMA slides. 
An interface for a robotic microscope was already designed by 
our group to handle so called digital cases, sets of digital images 
representing whole glass slides.  
Heavy modifications on the previous work were done to face 
TMA sample peculiarities. See Figure 10. 
Comparing to conventional digital slide, the pedant acquisition of 
entire slide section is useless, as information (tissue) is not con-
tinuously spread on the glass, rather spottily localized. At the 
same time, checking on the fly if an image contains or does not 
contain tissue is not an efficient solution; in fact, depending on 
camera target and on magnification it might happen that, pedanti-
cally acquiring the slide, a portion of tissue is always present. 
Therefore a different approach should be applied. 
Another aspect to be considered is the need to correctly associate 
each core section and, therefore the corresponding digital image, 
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to the proper donor tumor [37] that is a crucial issue in managing 
TMA slides. 
As described in section 3.3.1, misaligned tissue samples due to 
processing errors or tissue loss occur with varying degrees of fre-
quency but are almost always present even on the highest quality 
TMAs. Therefore the straightforward solution of applying a blind 
grid based acquisition is often not suitable and a non trivial solu-
tion for the automated core section assignment procedure is de-
sired.  
To address these aims, we implemented an image processing rou-
tine and an object recognition algorithm, working on an overview 
image of the entire slide. Each image can be automatically identi-
fied and acquired and, thanks to the information stored with the 
block array map in the database, associated to the proper tumor 
and the proper donor block. 
We tested the accuracy of the routines on a set of TMA pano-
ramic images. The object recognition algorithm we implemented 
revealed 96.8% of accuracy (5688 core sections out of 5878) (see 
0).  
This solution to automatically perform grid location assignment is 
particularly relevant and crucial; it allows high-throughput 
screening of TMAs speeding up the process and enhancing data 
quality related on the exact assignment of each tissue to original 
tumor. 
The Digital TMA Environment component also integrates image 
analysis routines to automatically evaluate protein expression on 
TMA tissue samples. 
 
The architecture of the Digital TMA Environment is reported in 
Figure 11. This custom made environment has been developed in 
Visual C++ in a modular way, to ensure re-usability of software 
components. Modularity allows adding, upgrading, and substitut-
ing components; for example a new camera could be integrated in 
the acquisition system, an image analysis routine could be up-
graded or a new one could be added. In particular, the DM LA 
Controller module can be substituted to interface different robotic 
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microscopy equipments, letting the system being hardware inde-
pendent. The two systems in use in Trento (Bioinformatics 
Group, ITC-irst and Santa Chiara Hospital, Pathology Depart-
ment) employ Leica DM LA Microscopes (Leica Microsystem, 
Wetzlar, Germany) coupled with 3-CCD Sony DXC 390P video 
cameras (Sony Inc, Tokyo, Japan). Matrox Meteor II MC acquisi-
tion boards (Matrox Electronic Systems Ltd, Dorval, Canada) 
digitize analog video signal. Software applications are executed 
on Personal Computer Pentium 4 processors - 1.6 GHz - with Mi-
crosoft Windows 2000 operating system. Leica DM SDK 4.1.4 
and Leica Video Autofocus libraries were used.  
 
The processing routine (segmentation plus object recognition pro-
cedure) was developed by applying image processing and analy-
sis operators contained in Aphelion 3.1e I mage Processing Li-
brary (ADCIS S.A., Hérouville Saint-Clair, France), and 
integrated in the Digital TMA Environment as ActiveX controls. 
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Figure 10 - Digital TMA Environment user interface: Step 1 frame 
corresponds to the already acquired slide selection to be processed 
by the object recognition algorithm; Step 2 frame represents the ob-
ject recognition output. Through the lower frame the output may be 
corrected or the algorithm may be run again with different parame-
ters. 
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Figure 11 - Digital TMA Environment 
Figure 12 - TMA slide automatic acquisition: from panoramic over-
view detection to single spot automatic evaluation. 
 
Panoramic acquisition and centre of coordinates 
A crucial issue of correctly creating this image archive in an 
automated way is that all stored single core section images must 
be properly linked to the specimen (donor block) from which the 
core was punched and therefore to the underlying clinical-
pathological information.  
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The entire automated process we propose as solution may be di-
vided into four fundamental steps: (1) acquisition of a low-
resolution digital image of entire glass slide (panoramic image); 
(2) identification of centre coordinates of each core section on 
panoramic image; (3) assignment of the correct position of each 
core in the matrix which topologically describes the microarray; 
(4) acquisition of single core section images at proper resolution 
in a correct ordered sequence. 
Each step is performed automatically. User intervention in pass-
ing from step (3) to step (4) is optional. In next sections steps (1)-
(4) are described in more detail. A screenshot of the Digital TMA 
Environment interface is shown in Figure 10. 
 
Panoramic digital image acquisition 
Low-resolution digital images of whole TMA slides are acquired 
capturing multiple regions of the slide. All digital images are 
758x570pixel, 24 bit, acquired at 2.5 magnification (NA = 0.07).  
These images are then digitally tiled together to create the result-
ing composite whole slide image (panoramic image). Before til-
ing, each image is automatically processed for shading correction. 
Image shading might be caused for example by non-uniform il-
lumination or non-uniform camera sensitivity; its elimination is 
recommended when image analysis and understanding are final 
goals. With our equipment the resolution of panoramic images is 
about 35µm per pixel (approximately 50 images are tiled). 
Identification of centre coordinates 
A digital image processing procedure automatically identifies the 
position of the centre of each core section in the panoramic im-
age. It works on the red component of colored panoramic image; 
thresholding and morphological operators are applied. A frame 
and an area filter are used together with a control on the number 
of segmented objects to automatically reduce the risk of detecting 
unwanted objects (noise) in the output binary image (for example 
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pen signs on a slide edge or air bubbles). These error sources are 
avoided firstly by using a rectangular frame to reject objects on 
the glass slide outside the region occupied by the array, and sec-
ondly by employing a bandpass area filter. The frame is deter-
mined during panoramic image acquisition step and surrounds the 
array region on the glass slide. The area filter automatically re-
moves too small or too large objects from the array region, when-
ever the number of segmented objects exceeds the declared num-
ber of core section (reference value for core section area 
comparison is computed by ( )22dπ , where d is the diameter of 
the needle). Once this procedure is completed, x and y coordi-
nates of the centre of gravity of each core section are available 
(see Figure 13a-d), as output of image processing procedure. 
The success of this feature extraction procedure is guaranteed if 
the values of two acquisition parameters, lamp intensity and dia-
phragm aperture, vary in predefined ranges of values. 
 
Object recognition and ordering algorithm 
 
The TMA construction procedure should produce regular block 
array sections, in which each core section position is easily recov-
erable from x- and y-spacing parameters. However, inconven-
iences occurring during block array sectioning and glass slide 
preparation complicate the object recognition procedure. Some 
examples of this kind of problems are reported in Figure 14. Dur-
ing the image processing procedure, some samples may be lost 
due to fragmentation, because of their too small dimensions, 
therefore contributing to the disorder of the panoramic digital im-
age. Nevertheless, even these cases contain precious information 
which an automated procedure should not loose.  
Therefore, efforts have been devoted to cover and solve these 
“disordered cases” in a way as more general as possible. The re-
sult of object recognition procedure is twofold: (1) the ordered list 
of the coordinates of the core section centres and (2) an index as-
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sociated to each array site (grid cell), which summarizes addi-
tional information. This information allows the user to detect 
cases for which grid assignment is doubtful. Mis-assignments 
may induce propagation errors in the ordering procedure. The 
user may benefit of this information to manually correct the or-
dering results.  
The object recognition procedure has a high degree of accuracy; 
therefore, in a large scale experiment as a TMA experiment is, we 
could use it with no manual intervention and automatically reject-
ing the few single core sections which are not properly located 
into the array. However, we developed an interactive module to 
recover these core sections.  
The interactive module also allows one to change some of the pa-
rameters of the segmentation and the object recognition routines. 
The user can change the range of bandpass area filter to recover 
cases in which the automatic procedure was not able to remove all 
noise. Moreover, core section diameter on the glass slide is some-
times larger than the declared value, especially in the case of 
1mm needle diameter. We found empirical reduced values for x- 
and y-spacing parameter which work better in case of enlarged 
core sections. The manual module allows switching between de-
clared and empirical x- and y-spacing values. Whenever one of 
these parameters is changed, a new run of the segmentation and 
object recognition is executed.  
The interactivity of our procedure is limited only to this manual 
module, which use is optional.  
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Figure 13 - Image processing procedure and result of object recog-
nition algorithm on the panoramic image of a TMA arranged into a 
Chapter 4 - The TMA data management system 
57 
 
single matrix of 7 rows and 10 columns. 
 
Figure 14 - Examples of panoramic images: (a) regular block array 
section (4 sub-matrix topology); (b) array with fragmented and lost 
core sections (single matrix topology); (c) distorted block array sec-
tion: lines highlight distortions different from overall grid rotation. 
Acquisition of single core sections image 
The ordered sequence of core section coordinates is the input of 
the single image acquisition procedure. The stage of the robotic 
microscope is automatically driven on the glass slide and stopped 
on each core section to acquire the corresponding digital image at 
selected magnification. TMA digital cases are therefore con-
structed by allowing the user to examine the single core section at 
the required magnification. This approach is similar to digital 
cases acquisition, where tissue images are more straightforward 
acquirable because tissue is continuous. Magnification selection 
depends both on pathologists’ needs (screen evaluation) and on 
image processing routine constraints, which automatically quan-
tify biomarkers expression (quantitative image analysis).  
Panoramic and single core section digital images are stored into 
the database. 
 
Routine validation 
To test the digital image processing and object recognition proce-
dure 85 panoramic images of breast cancer TMA, created at St. 
Chiara Hospital, Trento, Italy were acquired at ITC-irst, Trento, 
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Italy. Seventy-five sections were cut from block arrays prepared 
with 1 mm diameter needle and arranged into a 7x10 single ma-
trix (for an example, see Figure 14). The remaining sections origi-
nate from block arrays containing roughly 200 cores of 0.6mm 
diameter arranged in 4 sub-matrixes (for an example, see Figure 
14). Selected sections were cut from a total of 29 different block 
arrays.  
We identified the worst cases (17 cases) and used them as training 
set both for segmentation and object recognition algorithm. Con-
cerning the segmentation we optimized digital acquisition pa-
rameters (lamp intensity, diaphragm aperture) on the training set 
and tested them on the remaining 68 images (test set). Concerning 
the procedure for the identification of centre coordinates, we re-
port that the panoramic digital image acquisition takes about 4 
minutes for about 50 tiles (array dimension about 20x22mm). 
The segmentation algorithm correctly identified all core sections 
in all images. In fact, the optimal acquisition parameters found on 
the 17 training images allowed to successfully threshold all the 
test images in an automated way. For 12% of them the area filter 
was necessary to remove unwanted objects.  
Hereinafter we discuss the results of object recognition algorithm 
performed with the 68 test images previously mentioned. The per-
fomance values are summarized in Table 1. 
 
Table 1 - Object recognition algorithm performances. 
 Core sections (%) 
Number of grid cells 5878 
Number of correct assignments 5692 (96.84) 
Propagation errors 186 (3.16) 
Localization errors 49 (0.83) 
 
TMA automatic evaluation 
Image analysis routines are integrated in the system, to fully 
automatically evaluate biomarker expression on single core sec-
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tions. Automatic evaluations can then be stored in the database. 
Image processing algorithms are differently developed for spe-
cific cell compartment biomarker. These algorithms are not dis-
cussed in this work.  
After a slide has been digitized, automated evaluation can be per-
formed online (immediately after acquisition) or offline (later on), 
by choosing the slide code on a list of the already acquired slides 
and by choosing the automatic routine to work with. Each slide 
can be analyzed independently multiple times and all automatic 
outputs are stored in the database. Multiple evaluations can be 
necessary, for instance for markers staining both the cell mem-
brane and the stroma, or to compare new implemented routines. 
The image analysis routines included in the Digital TMA Envi-
ronment do not require technicians to set calibration parameters, 
which could affect successive expression measurements.  
However, the tissue heterogeneity (see section 5.3.1) may affect 
results of a fully automated evaluation and pathologist supervi-
sion is required to verify core section tissue. 
Details of the image analysis routines are not provided herein. All 
the work regarding image processing analysis was done by R. 
Dell’Anna (ITC-irst, Trento, I). 
 
4.2.3 System usage and availability 
In 2002 a prototype version of the system was in use in the de-
partment of Pathology of Santa Chiara Hopital, Trento, Italy. 
Since June 2003 the web version of TMABoost is in use. As of 
January 2005, there are 7 institutions (from Italy, UK, USA) that 
have used the system to evaluate TMA experiments. About 2500 
tumor cases (breast, ovary, and lung) are stored in the database 
and approximately 38000 TMA images have been evalauted. 
About 30 biomarkers have been evaluated on TMAs.  
Current studies are devoted to the assessment of the prognostic 
power of novel biomarkers for breast and ovarian cancer. The 
prognostic significance of the Herceptest® on breast carcinomas 
on TMA was recently assessed [66].  
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A finite time period demo access to the web system can be re-
quested at the web site [20]. About 20 demo accesses have been 
allowed till December 2004. 
 
 
The object recognition and the ordering algorithm solution were 
presented at the CNIO Meeting 2003 [21] and a full paper was 
submitted to Computer Methods and Programs in Biomedicine. 
The TMABoost system was presented at Medinfo 2004 [60] and 
BITS 2004 [67] and a full paper was submitted to IEEE Transac-
tions on Information Technology in Biomedicine. 
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5. TMA Data Analysis 
Recently a significant amount of work has been done in the area 
of data analysis for expression micorarrays. This work has fo-
cused on preprocessing approaches (for example, different flavors 
of normalization and filtering techniques) and on unsupervised 
and supervised methods based on statistical or machine learning 
techniques. Interestingly, many of these approaches are applicable 
to TMA studies, where panels of proteins are evaluated on co-
horts of cases. All the critical issues of these methods were re-
cently reviewed [68][44][69].  
 
At a very high level, differences between expression microarray 
and TMA (see section 3.3) experiments can be mainly divided 
into qualitative and quantitative differences. The qualitative dif-
ference has to do with the kind of biological information involved 
in the experiments: contrarily to cDNA and oligonucleotide mi-
croarrays, immunohistochemical experiments with TMAs meas-
ure levels of proteins, and thus directly providing functional in-
formation of diseased cells in situ. As immunohistochemistry is 
routinely used in pathology laboratories throughout the world, 
TMA studies have the potential to be more translatable to a clini-
cal application such as the development of a diagnostic bio-
markers or a potential to therapeutic target. The quantitative dif-
ferences have to do with number of variables involved in 
experiments and with quantity of data produced, which are much 
more controllable and manageable. Variables into play are more 
likely to be under control (antibody specificity and tissue condi-
tions) allowing for higher data quality.  
 
Typically TMA studies involve histopathological and clinical 
variables (covariates), as when used to construct predictive mod-
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els. The protein covariates are studied for association with clinical 
parameters (tumor grade, tumor stage, survival, recurrence), and 
used along with clinical covariates in Cox regression models; see 
[70][71] and references therein. The very aim is to improve the 
predicting power of current prognostic models [40][72][73][74], 
using appropriate measures to compare the predicting power of 
them.  
Another application regards the investigation of proteins to be-
come powerful diagnostic biomarkers in clinical setting or of 
panel of proteins evaluated on same cohort of patients to define 
molecular profiles typical of disease progression (classification 
task). It either can be performed by using diagnoses as training 
labels or by using clinical outcomes (continuous training variable 
[17][18][75][76]). 
Moreover studies are focused on the discovery of unknown diag-
nostic sub classes (discovery driven studies). 
TMAs also play an important role in validation studies. There are 
now many examples of expression microarray and proteomic 
studies where TMAs are used to verify that the over or under ex-
pressed genes of interest are in fact differentially expressed in situ 
[77]. 
 
In this chapter we focus on practical aspects peculiar of TMA 
studies, regarding data quality assessment, data preprocessing and 
data analysis. In this context we consider automation respect to 
data quality.  
5.1. Preprocessing 
Integrated frameworks for the collection and management of data 
are of primary importance (see chapter 4), in particular if different 
types of data and many data sources are involved at distinct time 
points. Technological approaches can dramatically reduce the 
lack of homogeneity and errors in raw data, by applying consis-
tency constraints, completeness controls, etc. Examples are the 
consistency control of birth and death dates, of tumor organ site 
and histological diagnosis, of compatibility between block array 
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description data (patient replicates, rows and columns number) 
and number of donor blocks used during preparation, etc.. 
Nevertheless, beyond the implementation of such technological 
solutions which can partially solve the problem, data preprocess-
ing still remains a crucial phase of data analysis. 
Data cleaning, data homogeneity (distribution analysis), outlier 
detection, missing data replacement (imputing), normalization, 
etc. must be almost always performed and standard statistical 
techniques are well suited for these purposes. As a next step a 
qualitative overview of the dataset is a good step. 
One significant advantage in TMA data evaluation is being able 
to perform a visual inspection of the experimental data. Visual in-
spection can even help in detecting unexpected variations, which 
might be caused by errors or might be of biological interest. 
When multiple proteins are under investigation, conventional 
graphical representation such as distribution plots, box plots, etc, 
become too time-consuming.  
An excellent example of good intuitive graphical tools are heat 
maps, which have been extensively used in expression microarray 
data analysis [103]. They represent quantitative data in a color 
based approach, assigning incremental color intensities to even 
spaced value intervals of expression levels. Many features and 
many samples can thus be visualized in one shot (see Figure 30).  
It becomes more useful and interpretable if agglomerative hierar-
chical clustering is performed grouping samples based on proteins 
and/or vice versa. Hierarchical clustering output is graphically 
represented by dendrograms, which help in ‘ordering’ the heat-
map [103].  
The partitioning clustering technique is another example of clus-
tering [78], that explores for natural groups of samples in the pro-
tein space or vice versa. K-mean and k-metoid approaches both 
require the number of clusters (k) to be sought as input parameter, 
and work to maximize the between cluster variability and mini-
mize the within cluster variability until convergence. As far as the 
number of cases is manageable, comparison among single case 
assignments obtained with different k-values can be done, making 
Chapter 5  
64 
 
use of class labels. Figure 15 shows results of examples of a set of 
54 cases (belonging to 4 diagnostic categories), which were clus-
tered by a partitioning algorithm with three different k-values (k = 
2, 3, 4). 
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Figure 15 - Partitioning clustering: set of 54 cases (belonging to 4 
diagnostic categories), clustered by a partitioning algorithm with 
three different k-values (k = 2, 3, 4). 
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5.2. Data reliability/reproducibility 
Data reliability and reproducibility must be considered as part of 
the experimental design process and their assessment must be po-
sitioned before real experimental data acquisition. In the case of 
protein level detection by means of in situ antibody evaluation 
(on TMA samples), two approaches are adopted (see section 
3.3.2.1), human or automatic evaluation. Assuming that sample 
preparation procedures are reproducible, inter- intra-observer 
variability must be assessed, both for human and for automatic 
evaluations. 
5.2.1 Human evaluation 
Assuming that evaluators/observers are equally skilled (equal ex-
pertise), inter-observer variability can be explained by subjectiv-
ity (it is difficult to have absolute reference for nominal catego-
ries) [79]; intra-observer variability is probably ascribable to the 
contingency of the situation [80]. 
In our experience, good agreements between pathologists in 
evaluating immuno-stainings are obtained only if data are di-
chotomized. We experienced it on two sets of more than 230 
TMA core sections each, using kappa statistics (data are not pro-
vided). 
It is reasonable to think that with a lot of training inter and intra-
observer concordance could improve, but probably it will never 
be perfect. 
If one of the final goals of studying proteins on tissues is to use 
biomarkers in clinical routine, inter-observer variability is going 
to be a challenging problem to be faced (see, for example [81]). 
 
5.2.2 Automatic evaluation 
Image processing routines are increasingly applied for the evalua-
tion of gene and protein expressions, overcoming subjectivity 
problems and providing quantitative continuous data. Automatic 
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quantitative analysis algorithms are deterministic: given the same 
input, exactly the same output is expected.  
By automatic evaluation intra-observer variability is thus can-
celled and inter-observer variability (variability between two 
equipments) can be reduced or even avoided if accurate definition 
of settings is done.  
 
Usually automatic machines work as ‘black boxes’ and, so far as 
no human intervention is required, data reproducibility is certain. 
If it is not the case and human interaction is required (semi-
automatic systems), reproducibility must be assessed.  
We experienced the use of a commercial semi-automatic system 
for the acquisition and evaluation of digital images and protein 
evaluations on TMA samples (color probe based immunohisto-
chemistry). Quantitative data were provided by the image proc-
essing software, which evaluated four quantities for each core 
section (spot) despite the type of the marker (nuclear, membrane, 
etc.) (brown area detected, blue area detected, percentage of 
stained area, intensity). As the system has not means of distin-
guishing non tumor tissue from tumor tissue (benign, stroma, in-
flammation, etc), a pathologist reviewed all images. If needed, he 
circled the tumor tissue areas by hand and immediately reran the 
evaluation routine. 
 
Figure 16 – Semi-automatic environment. 
BLACK BOX 
SEMI- AUTOMATIC 
SYSTEM 
   TMA SLIDE 
     (N spots) 
HUMAN CALIBRATION 
SPOT1: readings 
SPOT2: readings 
…..  
….. 
SPOTN: readings 
We investigated this point asking five pathologists to separately 
make calibrations, provided the circling was the same. We looked 
at the outputs and at their discrimination of groups. Data, reported 
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A unique default setting is proposed by the company, but it is far 
from being suitable for each experiment.  
For each experiment (each slide) calibration/setting must be pro-
vided by a pathologist at the beginning of the automated evalua-
tion run (see Figure 16). The user is allowed to set many different 
parameters (Hue, Luminosity, and Saturation for Light Brown, 
Blue and Dark Brown) to calibrate the machine. This operation is 
based on his/her personal experience. Subjectivity comes again 
into play, being a potential drawback of this semi automatic sys-
tem. 
How do output data distributions and evaluation ranges change 
respect to initial settings? How do these changes affect further 
analyses (marker discriminative power against histotype-groups)?  
We investigated this point asking five pa-
thologists to separately make calibrations, 
provided the circling was the same. We 
looked at the outputs and at their dis-
crimination of groups. Data, reported in  
Appendix A, demonstrate that initial settings significantly affect 
discriminative power of biomarkers in distinguishing diagnosis 
groups. 
This result warns to carefully handle semi-automatic quantitative 
systems to obtain reliable data. 
 
5.3. TMA data peculiarities 
In addition to data reliability assessment requirement, two major 
sources of irregolarities are present when dealing with raw TMA 
data: 
We investigated this point asking five pathologists to separately 
make calibrations, provided the circling was the same. We looked 
at the outputs and at their discrimination of groups. Data, reported 
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- tissue heterogeneity (topological). Not biologically inter-
esting, but essential to be monitored (see the drilling prob-
lem, section 5.3.1). 
- protein expression heterogeneity (proteins are generally 
not equally expressed across tumoral tissue). This hetero-
geneity might be of biological interest (see the pooling 
problem, section 5.3.2) 
 
5.3.1 Drilling problem  
Tissue heterogeneity can cause changes in diagnoses going down 
into TMA paraffin block depth; it turns out that different cuts 
might contain different information. It obviously can happen with 
conventional slides too, but it is less likely to be a problem, be-
cause larger areas are available for evaluations. Moreover, con-
ventional slides are typically evaluated by pathologist, rather than 
automatically. 
On the contrary, automation in TMA based studies is almost 
compulsory and is becoming more and more common.  
How do these changes affect data analysis? We analyzed the 
‘drilling problem’ in prostate tissues and statistically compared 
results obtained on a bunch of biomarkers with and without pa-
thologist supervision of diagnoses (target diagnosis set versus pa-
thologist diagnosis set), obtaining statistically different results.  
It suggests that for spatially heterogeneous tissues, pathologist 
supervision to confirm hysto type of single spot is mandatory and 
that, therefore, the experimental procedure can not be totally auto-
matic. A solution to this problem might be provided by alternative 
quantitative automatic approach as [57] so far as appropriate bio-
markers to select tissue compartments are available [22]. 
Figure 17 shows how diagnoses change along the punches (z-axis 
of block arrays) in a prostate TMA. 
 
We investigated this point asking five pathologists to separately 
make calibrations, provided the circling was the same. We looked 
at the outputs and at their discrimination of groups. Data, reported 
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Figure 17 – Loss of target tissue along 72 TMA experiments: the 
figure represents one row along z-axis. 
We investigated this point asking five pathologists to separately 
make calibrations, provided the circling was the same. We looked 
at the outputs and at their discrimination of groups. Data, reported 
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5.3.2 Pooling problem 
Usually multiple punches from the same donor block (patient) are 
included in a block array both to improve the possibility to have 
valuable samples of each patient (even if some construction prob-
lems occurred, see section 3.3.1) and to better represent the bio-
logical variability of the protein expression. 
Several studies were proposed on this topic, trying to quantify the 
most appropriate number of replicates for different tumor types 
[27]. 
When TMA cuts are then stained multiple spots of each patient 
are evaluated for each protein. Figure 18 schematically represents 
how multiple markers TMA dataset looks like: data entries along 
one column do not contain information at the same level. 
Each data entry is of the form yl
ab
, expression level of protein b 
(marker) on patient a (case), read on replicate l. Number of repli-
cates can vary from case to case and marker to marker. 
How do these replicates be managed in further analysis? No uni-
versal rule exists. Replicates are usually pooled [40]: minimum, 
maximum, or mean value among replicates is used. Standard de-
viations from the mean value for each case can be evaluated as 
measure of spread of the protein expression. 
Pooling approach might be decided on the basis of prior biologi-
cal knowledge (pooling method should reflect knowledge about 
the biological action of the protein). For example, for the estrogen 
receptors ER marker, which expression is known to significantly 
improve patient outcome, ER positivity in one spot provides nec-
essary information, thus the maximum value among replicates can 
be chosen. 
But it is not often the case and alternative approaches should be 
applied.  
A reasonable alternative relies on the associations of the investi-
gated biomarker with one or more other parameters (biological, 
histological or clinical) being relevant for the study domain. Dif-
We investigated this point asking five pathologists to separately 
make calibrations, provided the circling was the same. We looked 
at the outputs and at their discrimination of groups. Data, reported 
in  
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ferent pooling choices may lead to different results, as we (data 
not provided) and others [104] experienced, at least as regards the 
statistical significance of the association. This approach strongly 
requires a validation step on other datasets and if the ‘choice’ 
holds, it must be preserved in the future (a kind of protocol). 
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make calibrations, provided the circling was the same. We looked 
at the outputs and at their discrimination of groups. Data, reported 
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Figure 18 –TMA dataset structure. 
To account for multiple measures of same case and marker, we 
propose a Bayesian hierarchical classification approach, described 
in chapter 6. 
 
5.4. Expression value dichotomization 
It is quite common [40] to dichotomize expression scores of bio-
marker evaluation, when interested in characterize low risk and 
high risk patients (both in univariate and multivariate analysis). 
The rationale is twofold: i. leading with pathologists’ evaluations, 
inter-observer variability is definitely high (dichotomization 
overcomes this problem) and ii. over or under expression of a 
biomarker is of easier biological interpretation.  
The drawback is that if you deal with automatic evaluated meas-
ures, which are quantitative and continuous, dichotomization 
wastes a lot of information that might be of interest. It is usually 
the case that anyhow, not enough cases are available to use con-
tinuous values in survival analysis. Provided that the continuous 
spectrum of values is of interest, a compromise would be the 
definition of ranges of values.  
In any case when dealing with dichotomization (or even discreti-
zation), appropriate cutoff values should be defined. Similar con-
siderations as for replicate pooling choices regarding biological 
prior knowledge (see 5.3.2) are here applicable [40]. Alternatively 
to Cox regression models, tree-predictors techniques can be ap-
plied [82] [83], leading to intuitive interpretable rule based mod-
els.  
 
 
We investigated this point asking five pathologists to separately 
make calibrations, provided the circling was the same. We looked 
at the outputs and at their discrimination of groups. Data, reported 
in  
74 
 
 
 
 
 
Chapter 6 - Bayesian Hierarchical Model 
75 
 
Chapter 6 
6. Bayesian Hierarchical Model 
 
6.1. Introduction 
Usually multiple punches from the same donor block (patient) are 
included in a block array both to improve the possibility to have 
valuable samples of each patient and to better represent the bio-
logical variability of the protein expression. Depending on tissue 
type and on the protein under study, intra-tumor variability is 
lower or comparable to inter-tumor variability (class variability). 
Variations among replicate expression values are commonly ig-
nored in TMA data analysis by straightforward pooling ap-
proaches. The mean, the maximum or the minimum among repli-
cates is usually adopted and the strategy is based on biological 
knowledge or on protein associations (see section 5.3.2).  
However it has been found [40], that different choices can lead to 
covariates with different significance levels in Cox regression 
[70]. 
Intra-tumor expression heterogeneity can provide additional in-
teresting information to the analysis task. In a probabilistic 
framework for example, accounting for intra-tumor variability, 
could alter the posterior probability of a case of belonging to a 
certain class (or could even change the predicted class), providing 
insight into the particular case study.  
 
When measurement occurs at different levels (see Figure 18), 
standard statistical techniques are not appropriate, because they 
either assume that groups belong to entirely different populations 
or ignore the aggregate information entirely.  
Hierarchical models provide a way of pooling the information for 
the different groups without assuming that they belong to pre-
cisely the same population [43]. Hierarchical models (also called 
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multilevel models) are used when information is available at dif-
ferent levels of observation units (as for example, in meta-
analysis of separate randomized trials). 
In our application field, TMA studies, each group represents a pa-
tient or a tumor. Elements of the group are the multiple measure-
ments of a protein evaluated on different spots (replicates). Mul-
tiple groups belong to the same class, for instance, a diagnostic 
class. A schematic view of the data structure is represented in 
Figure 19. 
 
Herein we propose a classification model, which accounts for in-
tra-tumor variability in a probabilistic framework. It is based on a 
one-way normal random effects model that is a special case of the 
hierarchical normal linear model.  
We applied a Bayesian approach for dealing with inter-
measurement variability. Such an approach is perfectly suited for 
managing, within the standard decision theory, the uncertainty af-
fecting the experimental data.  
We compare the performances of our model MHierBa to a standard 
Bayesian classifier model MStBa. The MStBa model is a Bayesian 
model for which we applied standard pooling strategies. Perform-
ances are evaluated on simulated datasets characterized by differ-
ent ratios of intra-variability over inter-variability (within and be-
tween groups variability). Performance evaluations are obtained 
for a one feature two class problem. We evaluated our approach 
also on a real dataset. 
Some considerations on the proposed approach are drawn at the 
end of the chapter. 
 
The model was implemented in the R statistical package [107]. 
6.2. Model definition 
Be ijx  the value of the replicate j  of case i , where 
repnj ,....,1= and kCNi ,....,1= , k  being the class index and 
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kC
N being the number of cases. Assume that for each case i , the 
ijx  are normally distributed, ijx ),(~
2
iiN σµ  and that replicate 
variances are all the same, 22 σσ =i  for each i . Also assume 
that the replicate means of each case iµ  are normally distributed, 
iµ ),(~ 2τMN . The linear hierarchical model is sketched in 
Figure 19.  
In the next sections we firstly describe the classification task and 
secondly the learning task. 
 
 
Figure 19 - Structure of the hierarchical model. 
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6.2.1 MHierBa Model : Classification 
 
By Bayes’s theorem, the posterior probability for a new case, 
repnR∈X , is 
 
)|()(
)|()(
)(
)|()()|(
k
k
k
kkkk
k CPCP
CPCP
P
CPCPCP
X
X
X
XX ∑== . 
 
To evaluate the posterior probability, the marginal likelihood 
must be solved:  
µτµσµ
µ
dMPPCP ),|(),|()|( 2∫= 2XX , 
the k-index of the class is omitted for simplicity. 
 
Under these conditions (normal distributions and equal replicate 
variances), 
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where 2
2 1σ=S  and 2
2 1τ=T . 
 
Applying simple algebra, 
 
( ) ( ) µµµµµππ µ dMMTxnxSTSCP j jj repjnrep ∫ ∑∑ ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −+−−+−= )2(
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2
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A new instance will be classified into the class with maximal pos-
terior probability. 
 
Generalization for the multidimensional case is easily obtainable, 
assuming the conditional independence of the features given the 
class. 
 
6.2.2 MHierBa Model : Learning  
We estimated the distribution parameters from the data. This ap-
proach is usually called empirical learning [84][85]; it is an ap-
proximation of the maximum likelihood estimation. 
Within groups, means and variances are straightforward evaluated 
as: 
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Between groups we applied the pooled estimate for the class 
mean: 
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The variance 2ˆcorrτ  includes two terms, respectively for between 
groups and within groups variances (inter-variability and intra-
variability, respectively). It is like purifying the variance by the 
measure variability.  
This point estimate of the variance is valid as far as the within 
group variability is comparable to the between group variability, 
i.e. as far as the population variance is comparable to single case 
variance.  
These choices (complete pooling) are reasonable when the ratio 
of between to within mean squares is not significantly greater 
than 1 (see [43]). 
 
6.2.3 MStBa Model : Classification 
For a standard Bayesian classifier, the likelihood of x, R∈x , is 
))(
2
1exp(
2
1)|( 22 MxCxP −−= ττπ ,  
being τ and M, the variance and the mean of the population dis-
tribution. 
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By Bayes’s theorem, we evaluate the posterior probability for a 
new instance, R∈x . The value x of each instance corresponds 
to the mean value among replicates, meanx (standard pooling strat-
egy). 
A new instance will be classified into the class with maximal pos-
terior probability. 
 
6.2.4 MStBa Model: Learning  
We estimated distribution parameters (means and variances) as 
k
kC
C
N
i
i
N
M
∑
=
µˆ
ˆ  and the variance 
1
)ˆˆ(
ˆ
2
2
−
−
=
∑
kC
i
i
N
Mµ
τ . 
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6.3. Synthetic data  
Simulated datasets had 2000 patients (1000 each class) and 5 rep-
licates each patient.  
All expression values were generated as normal random numbers 
with fixed variances ( 2kσ ) and with means being normal random 
numbers with means 90 and 140 and fixed variances 2kτ  . 
 
6.4. Validation of the MHierBa model 
To validate the model we performed three sets of experiments 
with different aims. 
 
I. CLASSIFICATION TASK: It is aimed to verify the per-
formances of the classifier MHierBa, under different distribu-
tion conditions for the two classes. We assumed model pa-
rameters as known.  
Experiments were made on synthetic data, with:  
2
2
2
1 == = kk ττ  and 2 22 1 == = kk σσ  (balanced); 
2
2
2
1 == ≤ kk ττ  and 2 22 1 == ≤ kk σσ  (unbalanced), with different 
values of 2kτ  and 2kσ . 
 
II. LEARNING TASK: It is voted to verify the empirical 
learning reliability (point estimation of the parameters). 
Classification performances are compared to the previous. 
Experiments were made on synthetic data. 
 
III. LEARNING: As previously, but on a real set of data.  
 
For all the experiments, the priors for the classes were set at 0.5 
and the decision threshold at 0.5, unless differently specified. Re-
sults of the experiments are reported below. 
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I set of experiments 
Ia. 
Evaluation of classification performances of the two models 
MHierBa and MStBa, equally varying the variances for the two 
classes for a bunch of parameter sets ( 2 2
2
1 == = kk ττ  and 
2
2
2
1 == = kk σσ ). Table 2 contains the data of the 8 runs we per-
formed. It reports the generating variances for the two classes, the 
confusion matrix of the classification, the accuracies and the 
mean value of the absolute differences of the posteriors (for each 
case). With balanced data no differences respect to the classifica-
tion accuracy are expected (by classification model definition). 
Table 2 – Classification performances on balanced simulated data-
sets. No learning applied. 
 Class 1, 
MCl1 = 90 
Class2, 
MCl1 = 140 MHierBa  and MStBa 
Mean of abs 
diff posteri-
ors 
 
2
1=kτ  2 1=kσ  2 2=kτ  2 2=kσ  
Conf matrix: 
[target, 
model] 
Accuracy  
848 152 1 600 100 600 100 150 850 0.849 0.0043 
821 179 2 600 200 600 200 166 834 0.827 0.0086 
837 163 3 600 300 600 300 160 840 0.838 0.0129 
847 153 4 600 400 600 400 159 841 0.844 0.0172 
834 166 5 600 500 600 500 143 857 0.845 0.0211 
819 181 6 600 600 600 600 176 824 0.821 0.0247 
926 74 7 300 100 300 100 80 920 0.923 0.0053 
907 93 8 300 300 300 300 81 919 0.913 0.0167 
 
Ib. 
Evaluation of classification performances of the two models 
MHierBa and MStBa, unequally varying the variances for the two 
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classes for a bunch of parameter sets ( 2 2
2
1 == ≤ kk ττ  and 
2
2
2
1 == ≤ kk σσ ). Table 3 contains the data of the 8 runs we per-
formed. It reports the generating variances for the two classes, the 
confusion matrix of the classification, the accuracies and the 
mean value of the absolute differences of the posteriors (for each 
case). Figure 20 shows the posterior probabilities of the cases 
(panel (a)) and the values of the misclassified cases by the two 
models (panel (b)). Data of experiment 5 (Table 3) are plotted. 
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Table 3 - Classification performances on unbalanced simulated datasets. No learning applied. 
Exp Class 1, MCl1 = 90 
Class2, 
MCl1 = 140 MHierBa MStBa MHierBa MStBa 
Mean of abs 
diff posteriors 
 2 1=kτ  2 1=kσ 2 2=kτ  2 2=kσ  Conf matrix [target, model] Conf matrix [target, model] Acc. Acc.  
911 89 911 89 1 300 100 600 100 121 879 121 879 0.895 0.895 0.0054 
931 69 909 91 2 300 100 600 200 146 854 183 817 0.892 0.863 0.0638 
939 61 909 91 3 300 100 600 300 98 902 152 848 0.920 0.878 0.0885 
953 47 902 98 4 300 100 600 400 76 924 157 843 0.938 0.872 0.1172 
951 49 913 87 5 300 100 600 400 84 916 154 846 0.933 0.879 0.1104 
958 42 912 88 6 300 100 600 500 59 941 158 842 0.949 0.877 0.1235 
956 44 901 99 7 300 100 600 600 64 936 183 817 0.946 0.859 0.1439 
918 82 826 174 8 600 100 600 400 95 905 197 803 0.911 0.814 0.1520 
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Table 4 - Classification performances on unbalanced simulated datasets. Parameters were learned from data. 
Exp. Class 1, MCl1 = 90 
Class2, 
MCl1 = 140 
Conf matrix:  
[target, model] 
Conf matrix:  
[target, model] Accuracy 
Mean of abs 
diff posteriors 
 2 1=kτ  2 1=kσ  2 2=kτ  2 2=kσ  MHierBa MStBa MHierBa MStBa  
949 51 914 86 1 300 100 600 400 83 917 156 844 0.933 0.879 0.1095 
904 96 821 179 2 600 100 600 400 103 897 194 806 0.900 0.813 0.1567 
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II set of experiments 
We performed the empirical learning of the distribution parame-
ters. Experiments are performed on the datasets of exp.5 and 
exp.8 of Table 3, two situations of unbalanced distributed data. 
Data are reported in Table 4. 
The estimated parameters in experiment 1 are: 
1
ˆ =kM = 89.78; 1,ˆ =kpoolM = 89.00; 
2
1,ˆ =kcorrτ =221.25; 2 1,ˆ =kmeanσ = 97.60;  
2
ˆ =kM =140.07; 2,ˆ =kpoolM =140.36;
2
2,ˆ =kcorrτ =266.59; 2 2,ˆ =kmeanσ =398.44. 
The estimated parameters in experiment 2 are: 
1
ˆ =kM =90.66; 1,ˆ =kpoolM = 89.32; 
2
1,ˆ =kcorrτ =534.54; 2 1,ˆ =kmeanσ = 99.67; 
2
ˆ =kM =138.14; 2,ˆ =kpoolM =137.15;
2
2,ˆ =kcorrτ =281.02; 2 2,ˆ =kmeanσ =410.72. 
 
We applied cross-validation with different choices of fold num-
ber. Accuracy values are reported in Table 5. 
Table 5 – Classification performances for unbalanced datasets 
evaluated by cross validation.  
Exp Fold number 
Accuracy (StDev) 
MHierBa 
Accuracy (StDev) 
MStBa 
As 1 10 0.932 (0.018) 0.88 (0.018) 
As 1 5 0.932 (0.012) 0.88 (0.016) 
As 2 10 0.90 (0.02) 0.85 (0.018) 
As 2 5 0.904 (0.012) 0.85 (0.009) 
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Figure 20 - Posterior probabilities (panel (a)) and misclassified data 
(panel (b)) of the models MHierBa and MStBa are plotted respect to the 
case index. No learning applied. Cases with index i ∈ [1, 1000] have 
target class 1C  and with index i ∈ [1001, 2000] have target class 2C . 
Panel (a) shows posterior probabilities of the cases, i.e. 
)|( ,imeank xCP for MStBa and )|( ikCP X  for MHierBa. Panel (b) shows 
misclassified data by each of the two models: meanx  values for the 
MStBa are reported (blue) and meanx  values and standard deviations 
for the MHierBa (red). Horizontal lines correspond to the mean values 
of the two classes. 
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Figure 21 - Posteriors are plotted against the evaluated means of the 
cases (xmean). Priors were evaluated from data. Panel (a) shows data 
of a balanced dataset ( 5.0ˆ,5.0ˆ 2 2,1
2
2,1 == == kk στ ). Panel (b) shows data 
of an unbalanced dataset ( 4.0ˆ,2.0ˆ,5.0ˆ 2 1
2
1
2
2,1 === === kkk σστ ). Vertical 
lines identify the values of the estimated class means Mˆ by the 
learning approaches of MHierBa and MStBa. 
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III set of experiments 
We applied our classification model to a prostate dataset com-
posed of 122 benign prostate tissues and 205 localized prostate 
cancer tissues. The α-Methylacyl CoA racemase (AMACR) pro-
tein was evaluated on this dataset. 
AMACR is a sensitive recently identified prostate cancer bio-
marker [22]. It is consistently over expressed in prostate cancer 
both at transcriptomic level and at proteomic level. AMACR is 
lower expressed in metastatic prostate cancer compared to local-
ized prostate cancer, as recently confirmed by fluorescent-based 
measurements [22]. 
The distributions of the AMACR dataset are shown in Figure 22. 
For the two classes, the case replicate data, the case variances and 
the means are reported. The estimated parameters of the two 
classes are: 
1
ˆ =kM =3.39; 1,ˆ =kpoolM =3.15; 
2
1ˆ =kτ =0.48; 2 1,ˆ =kcorrτ =0.135; 2 1,ˆ =kmeanσ =0.41; 
2
ˆ =kM =4.35; 2,ˆ =kpoolM =4.59;
2
2ˆ =kτ =0.58; 2 2,ˆ =kcorrτ =0.27; 2 2,ˆ =kmeanσ =0.36. 
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Figure 22 - The α-Methylacyl CoA racemase AMACR dataset dis-
tributions. Core section evaluations (row 1), variance values 2σˆ (row 
2) and means among replicates µˆ  (row 3) are plotted. 
 
 
 
Table 6 shows the performances on the whole dataset and Table 7 
shows the results obtained applying cross validation.  
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Table 6 - Classification performances on AMACR dataset. Exp. 2 
performed with priors evaluated from data (0.37, 0.63 respectively); 
exp 3 with decision threshold for 1C  equal to 0.7 and equal priors. 
Exp. Conf matrix:  [target, model] 
Conf matrix:  
[target, model] Accuracy 
Mean of abs 
diff posteri-
ors 
 MHierBa MStBa MHierBa MStBa  
99 23 100 22 1 56 149 59 146 0.7584 0.7523 0.1155 
91 31 86 36 2 45 160 34 171 0.7676 0.7859 0.1113 
87 35 70 52 3 39 166 27 178 0.7737 0.7584 0.1155 
        
Table 7 - Classification performances on AMACR dataset by apply-
ing cross validation. 
Exp. Folds Accuracy (StDev) MHierBa 
Accuracy (StDev) 
MStBa 
1 2 0.77 (0.04) 0.77 (0.06) 
2 5 0.79 (0.07) 0.78 (0.08) 
3 10 0.73 (0.10) 0.72 (0.11) 
 
Figure 23 – AMACR dataset posteriors plotted against the evalu-
ated mean of the cases (xmean). 
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6.5. Considerations 
These preliminary performance tests of the MHierBa give us some 
clues about the applicability of the model. 
The following considerations apply to a one feature two class 
problem.  
Regarding the classification model evaluation we observed that 
when classes are balanced (see I set of experiments) no differ-
ences in terms of classification rates are obtained (intrinsic into 
the model); however increasing differences in the posteriors are 
detected as the intra-variability (within group) increases 
),|()|( xmedioCPCP kk ≠X  for each k.  
As far as the classes are unbalanced the two models MHierBa and 
MStBa perform differently (see Table 3). As the difference in the 
class variances becomes larger, the MHierBa outperforms the MStBa. 
Misclassifications of the two models are different, as shown in the 
panel (b) of Figure 20.  
We then tested the reliability of the empirical learning on two un-
balanced datasets (see II set of experiments). We observed that 
the models have lower but still good performances (compare 
Table 3 and Table 4) and that they decrease more for the MHierBa 
than for the MStBa.. This can be explained by the fact that the hier-
archical model includes more parameters than the standard model, 
incrementing the learning effort. The observations made for the 
classification model evaluation still hold. 
When dealing with the real dataset (III set of experiments), we 
observe that classification performances of the two models are 
almost the same. Differences are present in terms of single case 
posterior as shown in Figure 23.  
 
Based on these very preliminary tests we can conclude that the 
proposed model works at worse as the standard Bayesian classifi-
cation model and that under some constraints it works better. The 
empirical learning of the parameters provides reasonable results. 
The interesting part of the approach is related to the posterior 
probability evaluations. Our model emphasizes the information 
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available at every level, accounting for the spread of the replicate 
measures. An extreme example is that our model differentiates 
between vectors as 90,90)(90,90,90,1 =X  and (90,90)2 =X  (award-
ing 1X ), whereas the standard approach does not. 
 
Future work will face the evaluation of the performances on other 
real datasets with different characteristics. Simultaneously the 
model will be test in a multi-features framework. Successively a 
complete Bayesian approach can be implemented. 
 
The proposed model is applicable on other domains. 
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7. Protein Expression in Human Cancer  
Here we report results from three datasets examining different 
biological or clinical questions. For each study we briefly de-
scribe the motivation of the study, the dataset, the analysis tech-
nique applied and the results obtained. The first two studies were 
aimed to investigate the role of two proteins, M-CAM and Jag-
ged1, as prognostic markers for ovarian and prostate cancer, re-
spectively. The third study evaluated the possibility of building a 
model to discriminate among different states of prostate cancer 
starting from a panel of 41 proteins; this third study was built on 
data from previous findings obtained using a combination of pro-
teomics and expression array analysis. Unsupervised approaches 
were applied to qualitatively investigate the data. Supervised ap-
proaches were adopted to build a classification model.  
 
7.1. M-CAM expression in ovarian carcinomas 
This study was conducted in collaboration with the Department of 
Experimental Oncology, National Cancer Institute, Milano, I, the 
Department of Histopathology, S. Raffaele Hospital, Milano,I, 
and the Department of Histopathology, Gynecological Surgery 
and Medical Oncology, S. Chiara Hospital, Trento, I. 
 
M-CAM expression in ovarian carcinomas is histologically re-
stricted to serous and undifferentiated tumors and is an independ-
ent marker of poor prognosis.  
Ovarian cancer is the most common gynecological malignancy 
causing fatality in western countries and the fifth leading cause of 
female cancer death. Despite progress in surgical and chemother-
apy treatment, the 5-year survival rate of all stages of ovarian 
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cancer has remained constant at 39% over the past 30 years. Tra-
ditional clinico-pathological criteria used to predict clinical out-
come are inadequate. Thus, great benefit is likely to result from 
the characterization of additional prognostic factors, more closed 
related to tumor biology. These biological factors may offer novel 
approaches to the identification of groups of patients that could 
benefit from more aggressive therapy or could become targets for 
a more rationale therapy. M-CAM is classified as a member of 
the Ig-CAM superfamily on the basis of the homology of the nu-
cleotide sequence [86] Cell-adhesion molecules (CAM) are in-
volved in tissue morphogenesis and in tumor progression of sev-
eral human neoplasms. Although the biological role of M-CAM 
in normal tissue and malignant tumors remains unclear, M-CAM 
has been suggested to play an important role in tumor progres-
sion, implantation and placentation [86]. 
The aim of the present study is to investigate the expression of M-
CAM in a large series of well characterized human samples of 
ovarian carcinomas, and to investigate if its expression at the tis-
sue level is related to pathologic and clinic characteristics, prog-
nosis and response to therapy. To do this we used a properly de-
signed tissue microarray and investigated M-CAM expression 
using a specific monoclonal antibody. 
 
7.1.1 Material and method 
Patients and tumor specimens. To analyze the clinical and 
pathological significance of M-CAM expression we selected a se-
ries of formalin-fixed paraffin-embedded tissue blocks of 130 
surgically resected ovarian carcinomas. All cases had been oper-
ated between 1992 and 1999. All histological sections and paraf-
fin blocks were obtained from the Departments of Pathology of 
the S. Chiara Hospital of Trento and of the Borgo Trento Hospital 
of Verona. One pathologist with peculiar skill in gynecological 
pathology reviewed all pathological data. For all cases complete 
clinical data, including long term follow-up, were available from 
the Departments of Gynecological Surgery and Medical Oncol-
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ogy of the S. Chiara Hospital of Trento and of the Borgo Trento 
Hospital of Verona. The series included serous papillary (82 
cases), endometrioid (12), clear cell (13), indifferentiated (13), 
mucinous (6) and other (2), NA 5. Al cases have been staged ac-
cording to FIGO criteria: 26 were stage I, 14 stage II, 68 stage 3 
and 21 stage 4, and 4 NA. All cases were treated with platinum 
based therapeutic schedules. Response to therapy was known for 
99 patients and was scored as complete (58 cases), partial (22), 
minimal (1) or absent (18). Clinico-pathological data of all pa-
tients and of the subgroups of serous papillary cases and of cases 
which showed complete or partial response to treatment are sum-
marized in Table 8, Table 9 and Table 10 respectively. 
Tissue microarray construction. One representative tissue block 
for each tumor was selected and 4 tumor areas were identified on 
the corresponding histological slide and dotted on the slide. These 
dots were used to generate TMA blocks using a manual TMA in-
strument (Beecher Instruments, Inc., Sun Prarie, WI). Each TMA 
was designed to include 4 punches (needle diameter 0.6 mm) 
from each paraffin block, as well as a series of appropriate con-
trols. 
Immunohistochemistry and scoring system. Five micron sec-
tions of the TMA were prepared and immediately processed. 
Prior to immunostainings, sections underwent heat induced epi-
tope retrieval using citrate buffer, as previously described [87]. 
Immunostaining was performed using a specific anti M-CAM 
monoclonal antibody and the D07 anti p53 monoclonal antibody, 
followed by a sensitive StreptABC detection system as previously 
described [88]. Positive controls for M-CAM staining were the 
endothelial cells within the samples [89]. Positive controls for 
p53 were done on cases of breast carcinoma with known p53 
overexpression [90]. Negative controls were obtained by omitting 
primary antibodies.  
The results of the immunostainings were read by two different 
observers at the multiheaded microscope. For each core biopsy 
the observers evaluated the visual intensity of staining (0=no 
staining, 1=faint staining, 2=moderate staining, 3= intense stain-
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ing) and the estimated percentage of reacting cells, which was 
subsequently categorized as follows: 0=non reacting cells, 1=1 to 
10% of reacting cells, 2=11 to 25% of reacting cells, 3=26 to 50% 
of reacting cells, 4= more than 50% of reacting cells. Moreover 
we recorded the precise cellular localization of the reaction prod-
uct, i.e: at the cell membrane or in the cytoplasm. A final immu-
nohistochemical score for membrane or cytoplasmic staining was 
obtained by adding the value of the intensity to the percentage 
category. We also evaluated if there was immunostainings of the 
stromal component of the tumors, which was graded from 0 to 3.  
All data concerning the tumor characteristics and the block array 
maps were previously stored in the TMAboost system (see chap-
ter 4) so as the immunostainings results as described above (in-
tensity and percentage for membrane, cytoplasma and intensity 
for stromal component). Immunohistochemical data were subse-
quently retrieved and analyzed in relation to pathological and 
clinical parameters and with relapse free (RFS) and overall sur-
vival (OS).  
We analyzed separately the immunostainings of the four core sec-
tions of each case, and recorded each value separately: thus the 
immunohistochemical analyses generated a maximum of 24 dif-
ferent values for each case (for each of the 4 cores we recorded 
intensity, percentage and score for membrane and cytoplasmic 
staining and evaluated also stromal staining). This prompted us to 
investigate as to how classify each case in the over or under ex-
pressed protein group. Because no previous hints were available 
we aggregated the replicates values by using minimum, mean and 
maximum and looked for correlations with pathological and clini-
cal parameters.  
 
Statistical analysis. For statistical analyses beside studying the 
whole population, we focused on some more homogeneous sub-
sets of patients which were grouped together on the basis of simi-
lar clinico-pathological parameters such as stage I and II, stage 3 
and 4, complete and partial responders and minimally and no re-
sponders.  
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Chi-squared test was used to analyze the correlation of M-CAM 
positive cases according to clinicopathological characteristics. 
Fisher test was performed between dichotomous variables (two 
by two contingency tables). 
Kaplan-Meier curves were used to estimate recurrence-free time 
and overall survival, and the log rank test served to assess 
whether curves differed significantly between groups. We per-
formed the analyses on the whole series of tumors, and on sub-
groups of tumors with homogeneous serous papillary histology, 
stage and type of response to therapy.  
Multivariate analysis. To analyze the recurrence risk and patient 
survival accounting for multiple clinicopathologic parameters and 
M-CAM expression, multivariate logistic regression was used. 
The Cox proportional hazards model was used to assess which 
covariates affected recurrence-free time and overall survival.  
For all analyses P-values less than or equal to 0.05 were consid-
ered statistically significant. Analyses were performed with the 
software package R [107]. 
Table 8- Pathological and clinical characteristics of the whole tumor 
series of ovarian neoplasms and their relation to M-CAM expres-
sion. 
 
 
Total  M-CAM 
negative 
M-CAM 
positive 
P value 
      
Mean age 
(57.75) 
  57.25 59.85 ns 
 <mean 57 34 23  
 >=mean 68 31 37 ns 
Stage Stage I and II 40 31 9  
 Stage III 68 24 44  
 Stage IV 21 11 10 < 0.001 
Histotype Serous papillary 82 35 47  
 Indifferentiated  13 3 10  
 Clear cell 13 12 1  
 Endometrioid 12 9 3  
 Mucinous 6 5 1  
 Other 2 2 0 < 0.001 
Grading Grade 1 and 2 61 36 25  
 Grade 3 and 4 63 27 36 ns 
Response to Responders  80 37 43  
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therapy 
 Non responders 19 12 7 ns 
P53 Score 0-4 62 42 20  
 Score 5-7 68 23 45 < 0.001 
 
Table 9 - Pathological and clinical characteristics of the serous pap-
illary ovarian carcinomas and their relation to M-CAM expression. 
 Total  CD146  
negative 
CD146  
positive 
P value 
Mean age (59) <mean 31 13 18  
 >=mean 47 21 26 ns 
Stage Stage I and II 15 10 5  
 Stage III 51 17 34  
 Stage IV 14 7 7 0.058 
Grading Grade 1 and 2 41 19 22  
 Grade 3 and 4 40 16 24 Ns 
Response to 
therapy 
Responders  42 20 32  
 Non responders 14 9 5 Ns 
P53 Score 0-4 34 19 15  
 Score 5-7 47 15 32 0.053 
 
Table 10 - Pathological and clinical characteristics of par-
tial/complete responders tumors and their relation to M-CAM ex-
pression. 
 Total  CD146  
negative 
CD146  
positive 
p value 
Mean age 
(57.75) 
<mean 38 20 18  
 >=mean 39 16 23 ns 
Stage Stage I and II 21 18 3  
 Stage III 49 13 36  
 Stage IV 10 6 4 < 0.001 
Histotype Serous papillary 52 20 32  
 Indifferentiated  6 2 4  
 Clear cell 6 5 1  
 Endometrioid 8 5 3  
 Mucinous 3 2 1  
 Other 2 2 0 0.1240 
Grading Grade 1 and 2 37 21 16  
 Grade 3 and 4 39 14 25 0.1111 
P53 Score 0-4 39 24 15  
 Score 5-7 40 12 28 < 0.01 
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Table 11 – M-CAM, univariate survival analysis. 
Variable Grouping P value HR 95%CI 
OS in the whole series of cases 
Stage I and II vs III and IV <0.00001 7.84 3.6-17.1 
Age  <median;>=median 0.024 1.65 1.06-2.57 
Response to ther-
apy 
Absent and min vs others <0.00001 0.165 0.0944-0.288 
Histotype Serous vs all 0.00383 2.12 1.26-3.56 
Grade  I and II vs III and IV 0.00494 1.91 1.21-3.02 
P53 MaxScore07 04vs57 0.104 1.44 0.924-2.25 
M-CAM  MaxCat 0vs123 0.000276 2.3 1.45-3.65 
RFS in the whole series of cases 
Stage I and II vs III and IV <0.00001 7.88 3.9-15.9 
Age  <median;>=median 0.412 1.19 0.775-1.84 
Response to ther-
apy 
Absent and min vs others <0.00001 0.179 0.102-0.316 
Histotype Serous vs all 0.00398 2.1 1.25-3.52 
Grade  I and II vs III and IV 0.00451 1.91 1.21-3.02 
P53 MaxScore07 04vs57 0.0147 1.74 1.11-2.72 
M-CAM MaxCat 0vs123  0.00099 2.12 1.34-3.35 
OS in the group of responders 
Stage I and II vs III and IV <0.00001 15.4 3.75-63.7 
Age  <median;>=median 0.123 1.54 0.883-2.68 
Histotype Serous vs all 0.002 2.99 1.44-6.21 
Grade  I and II vs III and IV 0.0283 1.89 1.06-3.38 
P53 MaxScore07 04vs57 0.155 1.50 0.854-2.62 
M-CAM MaxCat 0vs123  <0.00001 4.71 2.46-9.01 
RFS in the group of responders 
Stage I and II vs III and IV <0.00001 18.5 4.48-76.8 
Age  <median;>=median 0.628 1.14 0.657- 1.98 
Histotype Serous vs all 0.00173 3.03 1.46- 6.28 
Grade  I and II vs III and IV 0.103 1.61 0.904- 2.87 
P53 MaxScore07 04vs57 0.0728 1.68 0.947-2.97 
M-CAM MaxCat 0vs123  <0.00001 4.48 2.32-8.65 
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Figure 24 – Representative immunostainings of M-CAM in ovarian 
tissues. 
7.1.2 Results 
Patient population. The distribution of histological type, tumor 
stage and grade of the cases studied in this report roughly reflects 
the demographics of Italian population. Median follow-up was 48 
months. Response to therapy was available in 98 cases: 78 
(79.6%) cases were complete or partial responders, while 20 
(20.4%) were minimally or non responders. High stage (I and II 
versus III and IV), high grade (1 and 2 versus 3 and 4), histologi-
cal type (serous vs. other histotypes), and response to therapy 
were all associated with shorted relapse free and overall survival 
(RFS, OS) ( 
Table 11). Age was associate with worse OS only in the whole 
series of cases. High p53 expression (p53 score higher than 5) 
A
B
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was associated with shorter RFS in the whole series of cases and 
in the subset of serous tumors ( 
Table 11). 
M-CAM expression. M-CAM was expressed in neoplastic cells 
in 88 (66.1%) of the investigated tumors. Expression was mainly 
seen at the cell membrane (65 cases, 48.9%) and less frequently 
in the cytoplasm (27 cases, 20.3%). Membrane and cytoplasmic 
expression were strictly associated (P<0.00001). M-CAM was 
always expressed by endothelial cells and in 29 cases it was also 
expressed in stromal non vascular tissue. In M-CAM positive tu-
mors the percentage of cells with membrane reactivity ranged 
from 5% to 90% (median 30%) and staining intensity was distrib-
uted as follows: intensity 1 in 23 (17.3%) cases, 2 in 37 (27.8%) 
cases, and 3 in 5 (3.7%) cases. The M-CAM immunohistochemi-
cal score, showed following distribution: score 0 in 68 (51.1%) 
cases, 1 in 0 (0%) cases, 2 in 4 (3%) cases, 3 in 17 (12.8%) cases, 
4 in 9 (6.8%) cases, 5 in 12 (9%) cases, 6 in 18 (13.5%) cases, 
and 7 in 5 (3.8%) cases.  
M-CAM expression and clinico-pathological parameters. For 
statistical analysis, after extensive work to define the most appro-
priate and bias-free criterion (data not shown), tumors were con-
sidered positive for M-CAM if they had a score of 1 or higher in 
at least one of the TMA cores. M-CAM positivity was almost re-
stricted to serous papillary and undifferentiated carcinomas 
(P=0.0004, see Tab. I), and it was associated with higher stage 
(P=0.0001, Table 8) and with high p53 levels (P=0.0002, Tab 
I).When only serous tumors were analyzed, M-CAM positivity 
retained only borderline statistically significant association with 
higher stage and p53 over-expression (P=0.059 and P=0.053,  
Table 9). When only complete/partial responders were analyzed, 
M-CAM positivity was statistically significant association with 
higher stage and p53 over-expression (Table 10).  
M-CAM expression and patient survival. At univariate survival 
analysis, positive M-CAM was associated with shorter RFS and 
OS in the whole series of cases, as well as in the subgroup of se-
rous carcinomas (Table 10, Figure 25). By analyzing the group of 
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78 patients classified as responder to therapy, M-CAM positivity 
was strongly associated with shortened RFS and OS (P<0.0001) 
in the subgroup of responders tumors ( 
Table 11, Figure 26).  
 
 
Figure 25 - M-CAM expression: A. and B. overall survival analysis 
and recurrence free analysis in the whole series, and C. and D. in 
serous adenocarcinomas. 
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Figure 26 - M-CAM expression: A. and B. overall survival analysis 
and recurrence free analysis in responders. 
Multivariate survival analysis. At multivariate analysis, high 
stage and response to therapy which were associated with both 
shortened RFS and OS in the whole series of patients and in the 
subgroup of serous carcinomas; age was and independent prog-
nostic marker only for OS (Table 12). Analyzing the group of re-
sponder patients, high stage and M-CAM expression were inde-
pendent prognostic markers predicting early relapse and shorter 
OS (Table 12). In a separate multivariate analysis not taking in 
account the grade of the lesions, M-CAM expression was inde-
pendently associated with shorter RFS (P=0.0066). 
 
OS in the whole series of cases 
Variable Grouping P value HR 95%CI 
Stage I and II vs III and IV <0.002 10.735 2.4046-47.927 
Histotype Serous vs all 0.88 1.056 0.5200-2.144 
Grade I and II vs III and IV 0.73 1.106 0.6303-1.941 
Response to ther-
apy 
Absent and min vs others <0.00001 0.191 0.0958-0.380 
Age <median;>=median 0.022 1.890 1.0945-3.262 
M-CAM MaxCat 0vs123  0.5 1.213 0.6925-2.124 
RFS in the whole series of cases 
Stage I and II vs III and IV 0.00079 13.164 2.924-59.260 
Histotype Serous vs all 0.60000 1.214 0.585-2.518 
Grade I and II vs III and IV 0.89000 0.961 0.533-1.734 
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Response to ther-
apy 
Absent and min vs others 0.00057 0.322 0.169-0.613 
P53 MaxScore07 04vs57 0.24000 1.468 0.775-2.782 
M-CAM MaxCat 0vs123  0.57000 1.192 0.649-2.190 
OS in the group of responders 
Stage I and II vs III and IV 0.0270 5.68 1.219-26.45 
Histotype Serous vs all 0.1400 1.87 0.812-4.28 
Grade I and II vs III and IV 0.3500 1.34 0.724-2.48 
M-CAM MaxCat 0vs123  0.0081 2.65 1.289-5.44 
RFS in the group of responders 
Stage I and II vs III and IV 0.0025 9.95 2.245-44.10 
Histotype Serous vs all 0.2700 1.55 0.706-3.41 
M-CAM MaxCat 0vs123  0.0130 2.42 1.205-4.87 
Table 12 - Multivariate survival analysis. 
In the present study we demonstrate that M-CAM is expressed at 
the mRNA and protein levels in a relevant percentage of ovarian 
carcinomas. M-CAM is differentially expressed in the different 
tumor types, being associated with serous and undifferentiated 
histology. At the protein level, M-CAM expression is associated 
with higher stage of the tumors, and with poor prognosis. At mul-
tivariate analysis, we could also show that in patients, which re-
spond to therapy, M-CAM expression independently identifies a 
group of patients at higher risk of early relapse and death. 
Present data have multiple implications in ovarian cancer cell bi-
ology, histology and possibly selection of therapeutic targets. 
Based upon the known role of Ig-CAMs in cell adhesion, signal-
ing, and tumor progression in other human neoplasm, it is tempt-
ing to hypothesize a role for M-CAM in ovarian carcinogenesis 
and progression. However to date we are not aware of experimen-
tal data on cell lines or animal model, which could support this 
suggestion, but our data suggest that further studies could be im-
portant in elucidating this point. 
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7.2. Jagged1 
This study was conducted in collaboration with the Department of 
Pathology, Brigham and Women’s Hospital, Harvard Medical 
School, and the Children’s Hospital Informatics Program, Chil-
dren’s Hospital Boston, Boston, MA; with the Dana Farber Can-
cer Institute, Boston, MA, and the Departments of Pathology and 
Urology, University of Michigan School of Medicine, Ann Arbor, 
MI. 
 
Jagged1 Expression is Associated with Prostate Cancer Metasta-
sis and Recurrence. 
JAGGED1 is a NOTCH receptor ligand, recently identified [91] 
using a high throughput quantitative proteomic technique. This 
study describes the increased expression of Jagged1 protein in 
human prostate tumours and its associations with prostate cancer 
progression and metastasis. The findings support a model in 
which dysregulation of JAGGED1 protein levels plays a role in 
prostate cancer progression and metastasis and suggest that JAG-
GED1 may be a useful marker in distinguishing indolent and ag-
gressive prostate cancers. Herein all what concerns the characteri-
zation of JAGGED1 antibodies (specificity test, see section 
3.3.2.1) and its expression in cancers different than prostate is not 
reported. These aspects can be found in [92] together with more 
detailed biological discussion. In the following sections, analyses 
based on TMA experiments are reported. 
 
7.2.1 Material and method 
Case Selection 
Samples from 236 patients with benign, high-grade prostatic in-
traepithelial neoplasia and localized and metastatic prostate can-
cer were obtained from the rapid autopsy program and the radical 
prostatectomy series, respectively, of the University of Michigan 
Prostate Cancer SPORE Tissue Bank and assembled on tissue mi-
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croarrays as described previously (93, 94). A subset of 95 men 
with clinically localized prostate cancer was evaluated for asso-
ciations between JAGGED1 expression levels and tumor recur-
rence (as judged by a rise in prostate-specific antigen level). A 
total of 1,247 tissue microarray cores were evaluated. 
 
Immunohistochemical Analysis 
Immunohistochemistry was done on 5-µm sections prepared from 
paraffin-embedded tissue microarrays. Slides were successively 
soaked in xylene; passed through graded alcohols; washed in dis-
tilled water; pretreated with 10 mmol/L citrate (pH 6.0; Zymed) 
in a steam pressure cooker (Decloaking Chamber, BioCare Medi-
cal, Walnut Creek, CA); and washed again in distilled water. All 
additional steps were done at 25°C in a hydrated chamber. Slides 
were pretreated with Peroxidase Block (DAKO USA) for 5 min-
utes, blocked with 20% goat serum for 20 minutes, and treated 
with rabbit anti-JAGGED1 antibody (H-114, Santa Cruz Biotech-
nology) at 1:50 in DAKO diluent for 1 hour. After washing in 50 
mmol/L Tris-Cl (pH 7.4), antirabbit horseradish peroxidase-
conjugated antibody (Envision detection kit, DAKO) was applied 
for 30 minutes. After additional washing, immunoperoxidase 
staining was developed with a DAB chromogen kit (DAKO). 
Slides were counterstained with hematoxylin. 
 
Semiautomated Quantitative Biomarkers analysis 
Evaluation of JAGGED1 immunohistochemical staining was 
done with the Chromavision (Chromavision Medical Systems, 
Inc., San Juan Capistrano, CA) Automated Cellular Imaging Sys-
tem (ACIS II). The system combines automated microscopy with 
computerized image analysis to generate a continuous immuno-
histochemical staining score between 0 to 255 intensity units. 
Each tissue microarray core was reviewed to ensure that intensity 
measurements were taken from diagnostic regions (benign, high-
grade prostatic intraepithelial neoplasia, or cancer) and that stain-
ing scores obtained from non representative regions were ex-
cluded. Images of all tissue microarray cores used in this analysis, 
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including those stained for JAGGED1, can be viewed at a sup-
plementary web site 
(http://rubinlab.tch.harvard.edu/supplemental_data/JAGGED1/ind
ex.jsp).  
 
Statistical Analysis.  
Patient information, including pretreatment prostate specific anti-
gen values, clinical and tumor stage, radical prostatectomy Glea-
son score, and surgical margin status, was prospectively collected 
and stored. After radical prostatectomy, patients were assessed 
annually for prostate specific antigen recurrence-free survival 
with a cut point of _0.2 ng/ml to define biochemical evidence of 
micrometastatic recurrence or progression. Bivariate (univariate) 
analysis was done to examine the association of clinical and 
pathological parameters with JAGGED1 staining and recurrence-
free survival. Cox proportional hazards regression models were 
used to analyze the relationship between recurrence-free survival 
and preoperative variables. A backward selection procedure was 
implemented to select the most parsimonious model. A 0.05 sig-
nificance level was used for all decisions of significance. Analy-
ses were run with SPSS 11.0.1 (SPSS, Inc., Chicago, IL). Kaplan-
Meier analysis was used to establish prostate-specific antigen re-
currence-free survival. 
 
7.2.2 Results 
JAGGED1 Protein Expression Is Associated with Prostate Cancer 
Progression.  
To study the expression of JAGGED1 in human prostatic speci-
mens, immunostaining was done on high-density tissue microar-
rays containing benign prostatic tissues, localized untreated 
prostatic adenocarcinomas, and hormone-naive and -refractory 
metastatic tumors. Two samples from 18 different patients im-
printed in duplicate were represented in these tissue microarrays 
(giving a total of 4 measurements per patient and 72 per cate-
gory). The staining intensity of JAGGED1 was measured and 
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quantified with the Chromavision Automated Cellular Imaging 
System II. For each patient the minimum, maximum, and mean 
staining intensity among replicates of the same patient were 
evaluated. 
Figure 27 - Representative JAGGED1 immunostaining in prostatic 
tissue samples. 
Representative examples of staining for JAGGED1 in benign 
prostatic tissue, localized cancer, and metastatic tumor are shown 
in Figure 27. Mean JAGGED1 staining intensity was increased 
significantly in clinically localized prostate cancer (score = 94.2; 
SE = 1.8) versus benign prostate tissue (score = 79.6; SE = 2.8; P 
< 0.001) and again in metastatic tumor (score = 127.5; SE = 4.6) 
as compared with either clinically localized prostate cancer (P < 
0.001) or benign prostate tissue (P < 0.0005). There was no sig-
nificant difference between the mean JAGGED1 staining between 
hormone naïve (score = 126.2; SE = 3.8) and hormone refractory 
metastatic prostate cancer (score = 129.1; SE = 9.7; P = 0.79). 
The findings were unchanged when minimum or maximum stain-
ing intensities were evaluated; data for minimum, mean and 
maximum intensity measurements are summarized with error bars 
with 95% confidence intervals in Figure 28. These data demon-
strate an association between increased JAGGED1 expression and 
progression from localized to metastatic disease.  
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Figure 28 - JAGGED1 immunostaining in benign prostatic tissues, 
localized cancer, and metastatic hormone naïve and refractory can-
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cer (summary). Confidence intervals (95%) show normalized mini-
mum, mean and maximum protein intensity units of JAGGED1 as 
determine by quantitative evaluation of immunohistochemistry; 
bars, ±SE. 
 
High JAGGED1 Expression Is Associated with Prostate Cancer 
Recurrence after Radical Prostatectomy for Clinically Localized 
Disease.  
The increased expression of JAGGED1 in localized prostate can-
cer and the additional up-regulation in metastatic tumor suggested 
that JAGGED1 might be a useful tissue biomarker to facilitate 
differentiating indolent from more aggressive prostate cancer. To 
examine this possibility, an association was sought between 
JAGGED1 levels and prostate cancer recurrence, defined as an 
increase in prostate-specific antigen of 0.2 ng/ml after radical 
prostatectomy or the development of overt metastatic disease. 
JAGGED1 immunostaining was done on 3 previously validated 
tissue microarrays. Analysis was restricted to a subset of patients 
(n = 95) with clinically localized prostate cancer and 3 or more 
interpretable tissue cores, accordingly with [26]. Patient demo-
graphics, which are representative of the total tissue microarray 
cohort, are presented in Table 13. Among these 95 patients, 26 
(27.4%) experienced prostate-specific antigen failure as of Janu-
ary 2004. 
Table 13 - Clinical demographics of 95 men with localized prostate 
cancer (abbreviation: PSA, prostate-specific antigen). 
  N   % 
Median Age (years)  59 (range 43 80) 
<=4 17 (17.9%)  
and<10 56 (58.9%) 
Preoperative PSA (ng/ml) 
>=10 22 (23.2%) 
negative 54 (56.8%) Digital Rectal Examination 
positive 41 (43.2%) 
<=6 35 (36.8%) 
7 55 (57.9%) 
>=8 5 (5.3%) 
3+4 10 (10.5%) 
Gleason Score 
4+3 45 (47.4%) 
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negative 64 (67.4%) Surgical Margin Status 
positive 31 (32.6%) 
negative 90 (94.7%) Seminal Vesicle Invasion 
positive 5 (5.3%) 
negative 72 (75.8%) Extraprostatic Extension 
positive 23 (24.2%) 
Median Tumor Dimension (cm)  1.4 (range 0.2-3.6) 
no 69 (72.6%) PSA Failure (ng/ml) 
yes 26 (27.4%) 
   
 
The results of univariate analysis are shown in Table 14. Consis-
tent with prior studies, Gleason score, preoperative prostate-
specific antigen, extraprostatic extension, seminal vesicle inva-
sion, positive surgical 
margins, and digital rectal examination were all significantly as-
sociated with prostate-specific antigen failure at the univariate 
level. Interestingly, in univariate analysis, a strong association be-
tween prostate-specific antigen recurrence and high levels of 
JAGGED1 staining was found (relative risks of 2.55 with 1.55 
intensity cutoff, and 3.05 with 1.8 intensity cutoff). It should be 
noted that significant Ps were found for JAGGED1 only when 
maximum intensity values for each patient were used. The varia-
tion in staining across cores is consistent with the heterogeneous 
nature of prostate cancer and suggests that broad tissue sampling 
may be needed to maximize the predictive power of JAGGED1 
staining. A Kaplan-Meier analysis depicting the association be-
tween JAGGED1 (cutoff of 1.8) and the probability of prostate-
specific antigen free survival is shown in Figure 29.  
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Figure 29 - Kaplan Meier analysis of individuals with clinically lo-
calized prostate cancer expressing high (cutoff of 1.8) or low levels 
of JAGGED1 (log rank test, p=0.02). 
The best multivariate model predictive of prostate cancer specific 
recurrence after radical prostatectomy for clinically localized 
prostate cancer included extraprostatic extension (P = 0.0005; 
relative risk = 3.94), preoperative prostate-specific antigen (P = 
0.042; relative risk = 1.97), and JAGGED1 (maximum intensity 
values were used; P = 0.016; relative risk = 3.51). Hence, high 
JAGGED1 protein level is a strong independent predictor of pros-
tate cancer recurrence. 
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Table 14 - Parameters associated with prostate specific antigen re-
currence following radical prostatectomy for clinically localized 
prostate cancer. 
   95% CI 
 Univariate Analysis: p-Value 
Relative 
Risk 
Lower 
Bound 
Upper 
Bound 
Gleason Score (2 cat, <7) 0.014 4.06 1.21 13.6 
Preoperative PSA (3 cat) 0.025 2.43 1.31 4.51 
Tumor Dimension 0.082 2.08 0.89 4.83 
Extraprostatic Extension 0.0002 4.04 1.84 8.88 
Seminal Vesicle Invasion 0.012 3.38 1.24 9.17 
Positive Surgical Margins 0.0003 4.21 1.81 9.77 
Digital Rectal Examination 0.038 2.29 1.02 5.15 
JAGGED1 (cutoff=1.55) (Max) 0.041 2.55 1 6.48 
JAGGED1 (cutoff=1.8) (Max) 0.021 3.05 1.12 8.31 
Multivariable Analysis:         
Extraprostatic Extension 0.0005 3.94 1.84 8.40 
Preoperative PSA 0.042 1.97 1.03 3.79 
JAGGED1 (cutoff=1.8) (Max) .016 3.51 1.26 9.76 
7.3. Prostate Cancer Progression Profile 
This study was conducted in collaboration with the Department of 
Pathology, Brigham and Women’s Hospital, Boston, MA, Har-
vard Medical School, Boston, MA, the Children's Hospital Infor-
matics Program, Children's Hospital, Boston MA, the Dana-
Farber Cancer Institute, Boston, MA, the Department of Pathol-
ogy and Urology, University of Michigan, Ann Arbor, MI, Uni-
versity Hospital of Ulm, Ulm, Germany. 
 
The critical clinical question in prostate cancer research is to de-
velop means of distinguishing aggressive from indolent prostate 
cancer. Expression array technology has lead to the development 
of discrete molecular signatures at transcript level [95], but the 
development of a robust signature to characterize aggressive pros-
tate cancer has yet to be achieved. 
Starting from a panel of genes accordingly dysregulated at tran-
script and protein levels [96], we studied a model to predict pros-
tate progression. We performed in situ analyses of the correspon-
dent proteins using a prostrate cancer progression TMA. 
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Interestingly this subset was able to distinguish men with clini-
cally localized prostate cancer that were at highest risk to develop 
PSA-failure following surgery.  
This study also demonstrates that cross platform models can lead 
to predictive models. 
7.3.1 Material and method 
Case Selection 
We used a prostate cancer progression tissue microarray, de-
scribed in [97,22]. It is composed of benign prostate tissue, local-
ized prostate cancer, hormone naïve, and hormone refractory me-
tastatic prostate cancer. These cases came from well-fixed radical 
prostatectomy, lymph node, and metastatic prostate cancer speci-
mens from the University of Michigan (Ann Arbor, Michigan), 
the University Hospital Ulm (Ulm, Germany), and the rapid au-
topsy program (University of Michigan Specialized Program of 
Research Excellence (S.P.O.R.E.) in prostate cancer  
 
Biomarkers for Immunohistochemisty 
The majority of the biomarkers for this study were derived from a 
recent proteomics study. Refinement of this list of proteins in-
cluded coordinate over or under expression by cDNA expression 
array analyses [98][99][100][101]. Antibodies against 41 proteins 
were optimized for in situ tissue evaluation by immunohisto-
chemistry on archival formalin-fixed, paraffin-embedded mate-
rial. The 41 biomarkers are presented in Table 15. 
 
Semiautomated Quantitative Biomarkers analysis 
Protein expression was evaluated by immunohistochemistry using 
an automated quantitative image analysis system, ACIS II 
(Chromavision Medical Systems, Inc, San Juan Capistrano, CA, 
USA). The ACIS II consists of a microscope with a computer 
controlled mechanical stage. Proprietary software is used to detect 
the brown stain intensity of the chromogen used for the immuno-
histochemical analysis and to compare this value to the intensity 
of the blue counter stain used as background.  Intensity levels are 
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recorded as Intensity Units ranging from 0-255. Given the hetero-
geneity of the prostate tissue samples, the study pathologists used 
a computer-based selection tool to highlight areas within each 0.6 
mm core for analysis. To account for this heterogeneity, we 
evaluated four tissue cores for each case.  
In cases where less than three core where available, we substi-
tuted the data with the median value of the biomarker for this/that 
histologic subtype. The missing values can arise both from cor-
rupted core sections (i.e., technically inadequate) and from a 
change of diagnosis. Missing values were present in the dataset 
98 times in benign (13.3%), 130 times in localized prostate cancer 
(17.6%) and 6 times in the metastatic prostate cancer samples 
(0.8%). The change of histologic diagnosis was not a rare event 
and therefore supports the need to review all TMA cores (see 
chapter 5). As a pooling strategy we adapted the mean TMA core 
value for each patient. 
The diagnosis of the selected area was recorded in the database as 
either benign, localized prostate cancer or metastatic prostate can-
cer. Cores with only stroma or non-diagnostic areas were ex-
cluded from further analysis. The hematoxylin and eosin stained 
images from this tissue array are available for review at a sup-
plemental web site [102]. 
 
Statistical Analysis Clustering 
 
Hierarchical agglomerative clustering both on samples and genes 
separately was carried out using Pearson correlation as similarity 
measure and average linkage method [103]. Clustering was per-
formed using dChip software [104].  
 
Linear Discriminant Analysis (LDA) 
Fisher LDA was applied on the dataset of 41 genes to select genes 
[105,106] which discriminate among the diagnostics groups. Dis-
criminant analysis is a model-free supervised approach (no as-
sumption on data distribution are required), which uses both mul-
tivariate analysis of variance and discriminant procedure to 
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identify a linear combination of predictor variables that best char-
acterizes the differences among the groups. LDA computes the 
so-called canonical variables (or canonical discriminant func-
tions). The first canonical variable is the linear combination of the 
variables that maximizes the differences between the means of the 
groups (one dimension). The second canonical variable represents 
the maximum dispersion of the means in a direction that is or-
thogonal to the first canonical variable. The other canonical vari-
ables are generated in a similar manner. The number of canonical 
variables is given by the number of groups minus 1. Therefore in 
the current study with five tissue classes (i.e., benign, localized 
prostate cancer, hormone naïve metastatic prostate cancer, hor-
mone refractory metastatic prostate cancer, and metastatic small 
cell prostate cancer), we obtained 4 canonical variables. When the 
two first canonical variables account for a large proportion of the 
variability in the dataset, a good graphical representation of the 
group differences can be obtained plotting the data along the first 
and the second canonical variables. 
 
By applying a stepwise approach (adding and removing variables 
on variance evaluation), the most powerful subset of predicting 
variables can be defined. Stepwise selection begins by identifying 
the variable for which the means are most different and continues 
by adding the next best variable stepwise. Wilks’lambda method 
was used to control the entry or removal of predictor variables 
from the discriminant function. In discriminant analysis, prior 
probabilities were computed from group sizes. To measure the 
degree of success of the classification accuracy was evaluated. 
LDA was performed using R [107] and SPSS (SPSS Inc., Chi-
cago, Il.). 
We also applied separately feature selection algorithms to find 
most predictive marker set (diagnoses as class label); attribute se-
lection involves searching through all possible combinations of 
attributes in the data to find which subset works best for class pre-
diction. We used ‘Best First’, which iteratively adds attributes 
with the highest correlation with the class as long as there is not 
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already an attribute in the subset that has a higher correlation with 
the attribute in question; and ReliefFAttributeEval, which evalu-
ates the worth of an attribute by repeatedly sampling an instance 
and considering the value of the given attribute for the nearest in-
stance of the same and different class. It can operate on both dis-
crete and continuous class data. No significant differences were 
found. 
Table 15 - Data description: Mean values and Confidence Intervals 
for the 41 markers and the 5 groups. 
 BENIGN LPCa META WAP SM_CL 
 Mean CI (95%) Mean CI (95%) Mean CI (95%) Mean CI (95%) Mean CI (95%) 
ABP280 0.69 1.15 0.42 1.02 -1.61 0.71 -0.63 1.46 -0.57 0.02 
AMACR-p504 -0.87 0.21 0.76 1.05 -0.20 2.05 0.64 2.82 -0.36 0.32 
AR 0.19 1.92 0.37 1.57 -0.40 1.97 -0.44 2.14 -1.73 1.09 
BM28 -0.61 0.55 0.11 1.41 0.07 2.98 0.54 1.90 2.27 1.64 
BUB3 -0.06 1.20 0.42 1.10 -0.13 2.83 -0.82 3.35 0.27 1.73 
CAMKK -0.19 1.89 0.18 0.86 0.18 2.99 -0.05 3.08 -0.55 0.95 
CASPASE3 1.02 0.85 -0.30 1.15 -0.17 1.94 -1.35 0.84 -1.03 0.68 
CDK7 0.09 1.20 0.33 1.47 -0.58 2.39 0.19 3.00 -1.84 1.30 
DYNAMIN -0.07 1.74 0.73 1.05 -0.74 1.80 -0.83 2.25 0.25 2.74 
E2F1 -0.06 1.78 0.07 1.22 0.46 2.70 -0.56 2.02 -0.12 5.72 
E-CADHERIN 0.04 1.34 0.31 1.48 -0.66 2.00 0.64 2.13 -2.42 1.93 
EXPORTIN -0.02 1.27 0.24 1.44 -0.18 2.41 -0.21 3.96 -0.40 0.95 
EZH2 -0.57 1.03 0.08 1.31 0.00 2.24 0.45 1.76 2.77 3.89 
FAS -0.31 1.94 0.08 1.58 0.22 2.54 0.47 2.40 -0.49 1.15 
GAS7 -0.04 2.06 -0.09 1.49 0.05 2.27 0.24 2.83 0.12 3.13 
GS28 0.00 1.46 0.28 0.91 0.34 0.53 -1.00 4.36 -0.53 2.19 
ICBP90 -0.38 0.96 0.58 1.86 -0.47 2.30 -0.46 1.23 1.95 2.58 
INTEGRIN 0.42 2.11 0.18 1.25 -1.34 1.31 0.31 1.42 -0.40 0.43 
JAGGED1 -0.86 0.89 -0.30 0.47 1.11 0.98 1.23 2.20 1.15 0.74 
JAM1 0.10 1.48 0.06 0.85 -1.24 2.43 0.75 1.37 1.56 3.48 
KANADAPTIN -0.58 1.29 0.23 1.12 -0.24 1.69 1.66 1.34 -1.54 1.25 
KLF6 -0.07 1.40 -0.05 1.24 -0.62 2.66 1.11 2.60 -0.02 2.50 
KRIP1 -0.45 1.59 0.33 1.58 0.02 1.66 -0.15 1.90 1.57 6.30 
LAP2 -0.11 1.18 -0.02 1.14 -0.71 2.75 0.92 2.39 1.18 4.18 
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MCAM -0.31 1.22 0.05 1.50 0.93 2.72 -0.16 2.38 -1.32 1.42 
MIB1 -0.46 0.27 -0.17 0.52 -0.36 0.44 1.21 3.31 3.05 0.79 
MTA1 -0.29 1.04 0.67 0.93 -0.99 2.33 0.38 2.91 -0.32 2.51 
MUC1 -0.33 0.25 -0.30 1.28 -0.24 0.87 1.16 3.21 2.75 0.71 
MYOSIN-VI -0.56 1.11 0.24 1.73 0.58 2.10 0.49 2.66 -1.40 0.68 
P27 0.43 1.73 0.20 1.78 -0.26 2.05 -1.30 1.06 0.04 0.11 
P63-34beta-E12 1.29 0.46 -0.76 0.26 -0.77 0.24 -0.27 1.84 -0.34 0.48 
PAXILLIN 0.00 1.45 0.32 2.30 -0.92 0.95 0.31 2.50 0.18 1.08 
PLCLN -0.54 0.83 0.63 1.21 0.05 3.16 -0.29 2.27 0.04 3.39 
PSA 0.64 0.19 0.36 0.54 -0.27 1.84 -1.48 1.99 -2.57 0.07 
RAB27 0.81 0.50 0.30 1.44 -0.95 1.78 -1.16 0.64 -1.62 0.27 
RBBP 0.19 1.53 0.16 1.44 0.01 2.21 -0.75 3.52 -0.60 0.52 
RIN1 0.79 1.32 0.35 1.36 -1.16 0.51 -1.13 0.46 -1.11 0.25 
SAPKalpha -0.24 1.63 0.05 0.99 -0.09 2.78 0.22 3.14 1.36 2.75 
TPD52 -0.17 0.76 -0.04 1.35 1.22 2.42 -1.05 2.44 0.05 1.32 
XIAP -0.34 1.39 0.74 1.02 -0.90 1.58 0.58 2.35 -1.63 0.04 
ZAG 0.44 1.11 0.34 2.17 -0.93 1.58 -0.42 1.76 -1.33 0.19 
 
7.3.2 Results  
Hierarchical Clustering Results 
We performed high level analysis to check data quality present in 
the set of the 41 selected proteins. In particular, we investigated 
through hierarchical clustering if sufficient protein expression 
data could distinguish different states of prostate disease. Cluster-
ing was separately carried out on the samples and the 41 proteins. 
Highest levels of the sample tree (Figure 30) demonstrated good 
separation between aggressive prostate cancer states and clini-
cally localized prostate cancer (LPCa). The clustering also relia-
bly distinguished benign prostate tissue (BEN) from clinically lo-
calized prostate cancer (LPCa). Although the metastatic tumors 
clustered together, no clear subclusters were found for hormone 
naïve (META) and hormone refractory metastatic tumors (WAP), 
as demonstrated in Figure 30.Figure 30 - Protein Expression of 41 
genes Selected for Differential Expression in Prostate Cancer 
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Progression. 1a. A “heat map” showing the relative protein ex-
pression of 41 genes selected as highly likely to demonstrate dif-
ferential expression in prostate tissue samples along the spectrum 
of cancer progression.  Protein expression was determined using 
antibodies directed against the various genes and measured by 
immunohistochemistry. The protein expression was determined 
using a semi-automated image analysis system (ASCIS II, Chro-
mavision), which measures staining intensity along a continuous 
scale from 0 to 255. Low and high expression are depicted using 
light green and bright red, respectively. Hierarchical clustering of 
the samples demonstrates good but not perfect ability of this 41 
gene panel to distinguish between the classes. 1b. Demonstrates 
that while some sub-types of metastatic prostate cancer (small cell 
cancer, upper figure, 200X original magnification) had discrete 
profiles, the clustering did not accurately distinguish between all 
of the hormone naïve and hormone refractory prostate tumor 
samples.  Interestingly, a high-grade, clinically localized prostate 
cancer (Gleason pattern 4 prostate cancer, lower figure, 200X 
original magnification) was found to cluster more closely to the 
metastatic samples using this 41 gene profile. Two cases of me-
tastatic small cell prostate cancer (SM_CL) clustered together 
(Figure 30b, top image). A sample of localized prostate cancer 
(LPCa_442-GL_7) was naturally grouped with the metastatic tu-
mors.  Although the overall Gleason score for this case was 7, the 
sample analyzed for this study depicted in Figure 30b demon-
strates pure Gleason pattern 4 prostate cancer consistent with a 
high-grade tumor.  When clustering genes based on samples, it is 
notably a group of seven genes over-expressed in benign tissues 
and under-expressed in aggressive cancer (p63, ZAG, ABP280, 
RAB27, RIN1, CASPASE3 and PSA). Extreme over and under 
expression of these proteins are present for aggressive cancer 
types (Figure 30, left side), supporting the hypothesis that the in-
vestigated set of markers might distinguish aggressive from indo-
lent prostate cancer. The heatmap also suggests that some genes 
provide redundant or partially redundant information, as con-
firmed by descriptive statistics presented in Table 15. 
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Figure 30 - Protein Expression of 41 genes Selected for Differential 
Expression in Prostate Cancer Progression. 1a. A “heat map” show-
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ing the relative protein expression of 41 genes selected as highly 
likely to demonstrate differential expression in prostate tissue sam-
ples along the spectrum of cancer progression.  Protein expression 
was determined using antibodies directed against the various genes 
and measured by immunohistochemistry. The protein expression 
was determined using a semi-automated image analysis system 
(ASCIS II, Chromavision), which measures staining intensity along 
a continuous scale from 0 to 255. Low and high expression are de-
picted using light green and bright red, respectively. Hierarchical 
clustering of the samples demonstrates good but not perfect ability 
of this 41 gene panel to distinguish between the classes. 1b. Demon-
strates that while some sub-types of metastatic prostate cancer 
(small cell cancer, upper figure, 200X original magnification) had 
discrete profiles, the clustering did not accurately distinguish be-
tween all of the hormone naïve and hormone refractory prostate 
tumor samples.  Interestingly, a high-grade, clinically localized pros-
tate cancer (Gleason pattern 4 prostate cancer, lower figure, 200X 
original magnification) was found to cluster more closely to the me-
tastatic samples using this 41 gene profile. 
 
Linear Discriminant Analysis 
In order to verify the discriminative power of the genes in terms 
of cancer progression and to identify gene profiles specific for lo-
calized prostate cancer and advanced prostate cancer, we devel-
oped a predictive model based on protein expression. Linear Dis-
criminant Analysis (LDA) was applied to identify a linear 
combination of predictor variables that best characterizes the dif-
ferences among the groups.  Clear separation of the groups was 
found as depicted in Figure 31. The first and the second canonical 
variables cumulatively account for the 91.7% of the variance 
(68.1% and 23.6%, respectively). This result suggests that differ-
ent groups (benign, localized cancer, hormone naïve metastases, 
hormone refractory metastases and small cells) are linearly sepa-
rable in the gene space.  
Stepwise linear discriminant analysis identified a set of 12 genes 
from the original set of 41 studied genes that best predicted tumor 
progression (Table 16) using 52 cases. Figure 31b represents the 
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cases along the first and second canonical components, which ac-
count for a cumulative variance of 87.9%. 
The discriminative power of the 12 gene model was not decreased 
with respect to the 41 gene model, confirming also the redun-
dancy of information provided by some genes; alternative subsets 
of genes from the 41 gene set could be selected. For example in 
the current study, after removing the 12 gene model from the 
original 41 genes, we can also identify good models with the re-
maining genes. The reason for associated gene expression pat-
terns may be explained by the activation of similar molecular 
pathways or general processes such as proliferation or apoptosis.  
Even though the model accuracy evaluated by cross validation 
(both using training and test sets 2/3 to 1/3 and leave-one-out) 
was very good, reliable performances should be assessed on a dif-
ferent larger dataset. 
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Figure 31 - Stepwise linear discriminant analysis (LDA) identified a 
group of 12 genes that best predict prostate cancer progression. (see 
Table 16). The heat map for these 12 genes is depicted in Figure 31a. 
Figure 31b represents the cases along the first and second canonical 
components of the LDA, which account for a cumulative variance of 
87.9%. The discriminative power of the 12 gene model was not de-
creased with respect to the 41 gene model, confirming also the re-
dundancy of information provided by some genes. 
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Table 16 - Stepwise LDA data: Fisher linear discriminant function 
coefficients (classification model). 
 
 GROUP 
 BENIGN LPCa META WAP SM_CL 
ABP280 (FLNA) 12,05 1,74 -16,81 -10,88 -8,60 
AMACR 3,18 3,80 -10,10 -1,78 -14,03 
CDK7 3,39 1,51 -2,94 -3,56 -19,28 
ITGA5 -7,43 3,77 -2,73 9,44 0,27 
JAGGED1 -10,04 -1,60 11,47 11,76 13,77 
KANADAPTIN -2,57 0,49 0,00 6,20 -3,41 
MIB1 (MKI67) -6,06 -4,08 5,75 8,76 32,84 
MTA1 2,18 2,32 -8,73 0,02 -3,26 
MUC1 -12,92 3,43 4,59 12,31 19,73 
p63 41,51 -10,06 -24,94 -31,61 -49,72 
PSA(KLK3) 11,82 2,26 -7,45 -14,78 -38,07 
TPD52 2,07 -4,91 6,93 -3,88 12,23 
(Constant) -42,68 -9,22 -42,86 -47,72 -170,25 
 
Expression Array Validation 
In an approach described by Ramaswami et al. [8], the ability to 
distinguish between localized tumors likely to be aggressive from 
those that cured by surgery was successfully assesses at RNA ex-
pression level. Analysis was performed on a publicly available 
dataset of 80 localized prostate tumors [108] (data not provided). 
 
7.4. Follow-up of the studies 
The above described studies also served as starting points for fur-
ther investigations, aimed to validate the results, to broader inves-
tigate the application of the analyzed proteins. They also encour-
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aged the application of different experimental technique. Some 
details of the follow up of the studies are here reported. 
  
M-CAM – This study has been submitted to Clinical Cancer Re-
search. The next step will be the investigation of ß1 integrine ex-
pression. Experimental data [109] suggest that M-CAM could re-
duce ß1 integrine expression on cell membrane. A confirmation 
on our cohort would partially explain the poor prognosis associ-
ated with M-CAM expression. 
 
 
Jagged1-This study was published in Cancer Research. The study 
has lead to the development of a funded pilot proposal by the 
Dana Farber Harvard Prostate Cancer Specialized Program of Re-
search Excellence (SPORE). This work will try to validate the 
significance of Jagged1 as a prognostic indicator using a clinical 
dataset from Sweden with over 20 years clinical follow-up. Ex-
perimental studies will also explore the development of a urine 
Jagged1 diagnostic test for the presence of high-grade prostate 
cancer and the use of an inhibiter of Notch signaling to decrease 
prostate cancer cell growth in vitro.  
S Santagata has been selected to receive the 2005 Stanley L. 
Robbins Memorial Research Fund Award for the project, "The 
role of JAGGED1 in prostate cancer progression". 
 
Prostate Cancer Progression - The multigene model study will be 
presented as platform presentation at the USCAP (United States 
and Canadian Anatomic Pathology) meeting in San Antonio, 
Texas (2005) and at the Prostate Cancer SPORE meeting in 
Houston, Texas (2005). The Rubin laboratory is also in the proc-
ess of developing a multiplex expression array test using a novel 
nanotechnology (Luminex) for the development of a tissue-based 
assay that could be applied on biopsy samples. 
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Chapter 8 
8. Conclusions 
Comprehensive analysis of protein functions in the context of 
their tissue environment will lead to the rapid identification, char-
acterization, and development of novel diagnostic markers and 
therapeutic targets. 
The investigation of molecular markers in surgical pathology has 
traditionally been accomplished by testing one marker at time on 
histological sections of tissues using immunohistochemistry or 
nucleic acid hybridization techniques. Each new marker had to be 
tested on multiple tissue samples. This was associated with the 
cost of each experiment, the variability between samples analyzed 
in the experimental run, and the added time associated with pre-
paring and evaluating these samples.  
The Tissue Microarray technology overcomes these limitations. 
Hundreds of individual tissue specimens can be arrayed on a sin-
gle glass slide, which can be further probed and analyzed micro-
scopically using the same standard laboratory methods (immuno-
histochemistry or in situ hybridization). These techniques allow 
simultaneous analysis of protein and RNA expression patterns in 
their tissue environment, as well as DNA profiling, making possi-
ble comparative studies. 
High-throughput microscopic studies can be performed using less 
sample material, and a fraction of the reagents needed to visualize 
the target. Another important advantage is that TMAs produce 
uniform staining of multiple tissue sections on one slide, resulting 
in enhanced reproducibility. The conditions for each sample in a 
TMA are therefore uniform in contrast to the standard slide ap-
proach. 
Immunohistochemistry is used to in situ determine the expression 
of proteins, which ultimately determine cell function. As immu-
nohistochemistry is routinely used in pathology laboratories 
throughout the world, TMA studies have the potential to be more 
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translatable to a clinical application such as the development of 
diagnostic biomarkers or a potential to therapeutic target.  
In TMA experiments, as with all high throughput techniques, high 
quality experimental data production is extremely important for 
the reliability of data analysis. This critical issue needs to be ad-
dressed on two levels, i. critical assessment of experimental de-
sign and organization and ii. reliability assessment of experimen-
tal data together with data pre-processing. In order to best deal 
with these two issues, a technological approach is advisable to 
properly manage data heterogeneity (biological, clinical and tech-
nical variables), data quantity and user diversity. This last aspect 
becomes even more crucial if data sharing occurs among and 
within research groups. Technological aspects may include auto-
mation to speed up data acquisition and evaluation that can be of 
great impact in overcoming TMA studies bottlenecks.  
 
To efficiently and practically face the above mentioned problems 
a strong interdisciplinary effort must be taken. Lack of integration 
and uncontrolled data collection activities not only affect study 
results, but may also complicate the future ability to share data 
from the same patient or same protocols. This has in the past been 
the reason why experiments were often repeated unnecessarily on 
the sample patient cases with an associated financial and sample 
cost. 
 
There are three critical issues related to the standard needs and 
requirements of TMA experiments: i. TMA studies may often in-
volve considerable numbers of patients, heterogeneous data are 
involved, and different kind of users, often from different institu-
tions, interact at different times; ii. TMA technology is prone to 
errors (association errors in designing the block array or evaluat-
ing a slide may easily occur) and iii. patients included in a TMA 
study (included in one block array) might be later on included in 
some other TMA studies or tissue based studies. 
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The technological solution we designed to address these require-
ments is a system that is i. patient centered and not experiment 
centered, ii. Work-flow oriented accounting for all phases of 
TMA experiments, iii. automated and iv. Web-based to allow for 
easy access and strong inter-institutional capabilities.  
The latter characteristic is crucial when multiple institutions 
and/or department collaborate on specific studies. The patient 
centered solution gives great advantages in efficient data retrieval, 
both as TMA studies are usually based on several single experi-
ments on the same cohort of patients and for new experiment de-
sign. In fact, this peculiarity enables the optimization of experi-
mental designs by exploring tumor availability, easily 
constructing new defined experiments on sub-cohorts of patients 
by selecting cases and expression data across distinct TMA ex-
periments, and further implementation to manage different ex-
periment techniques directly sharing all the available data by sim-
ply adding new modules. 
A key point that differentiates our approach from other solutions 
is the object recognition and ordering algorithm we integrated in 
the digital TMA acquisition system to automatically identify and 
associate each tissue sample with proper clinical information 
stored in the database. We favored the use of fully automated ap-
proach respect to semi-automated one to extremely speeding up 
the acquisition of single core section digital images by avoiding 
manual intervention. Regardless of the care and expertise used to 
create a TMA, some level of disorder with respect to the align-
ment of the tissue samples may arise, which forces the TMA 
technician to spend hours in appropriately aligning predefined 
grids, which has been used by most acquisition systems to date. 
Our system has the added advantage of being able to identify the 
tissue cores based on image recognition and knowledge of the 
TMA structure.  
The TMABoost prototype system is in use since June 2003; up to 
now about 550 TMA experiments were supported by the system. 
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Most of the technological limits of our prototype system may be 
solved by industrial stage porting. Performances of the digital ac-
quisition system can be bettered by interfacing different hard-
ware. For example, scanner devices, which have better speed per-
formances and are easy to use. An assessment of the 
performances of the automatic routines integrated in our system 
must be carried out using TMA slides prepared in other laborato-
ries.  
Up until now, data retrieval for analysis was always performed 
‘off-line’. Future work will focus on implementing on line data 
retrieval, to allow users to retrieve datasets through structured pa-
rametric queries. 
Another aspect that must be implemented in the next future is the 
possibility to handle data ownership. This would include the pos-
sibility to share or separate data based on study and sample per-
missions. This becomes more critical as the database is used by 
multiple research groups at different institutions. 
This thesis also addresses TMA data pre-processing issues.  
Integrated frameworks for the collection and management of data 
are always of primary importance to ensure data quality. It applies 
in particular if different types of data and many data sources are 
involved at distinct time points. Technological approaches can 
dramatically reduce the lack of homogeneity and errors in raw 
data, by applying standardized consistency constraints and com-
pleteness controls. Nevertheless, they can only partially solve the 
problem and data preprocessing still remains a crucial phase of 
data analysis. 
We identifying critical points and some solutions, tested on three 
TMA studies driven by different biological/clinical questions. We 
also evaluated applicability of automatic evaluations and ad-
dressed some of their limitations. Automation of TMA acquisition 
and evaluation process is highly desirable, but a fully automated 
approach is not currently possible and pathologist supervision is 
still required to obtain high quality data. 
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We also focused on a data analysis task. One particular problem 
to TMA studies is that there are usually multiple measures of the 
same protein for each patient, which are included in TMA dataset 
in order to account for tissue heterogeneity. We propose a novel 
classification model based on a Bayesian hierarchical approach, 
able to handle this kind of data uncertainty. This model was tested 
on two class problem simulated data, giving interesting results in 
terms of performances and output information. The next investi-
gation step is validating the proposed model in a multi-feature 
classification framework and in other application domains. 
 
This work highlighted many open issues in dealing with Tissue 
Microarray high throughput technology and proposed possible so-
lutions. Some aspects concern general experimental requirements.  
In our experience, dealing with high throughput technology ex-
periments imposes interdisciplinary effort. Drawbacks in the high 
throughput setting are mostly due to organizational issues, rather 
common in the bioinformatics field, and lack of integrated solu-
tions to properly make sense of huge and diverse data. This is par-
ticularly true if multiple institutions collaborate on same studies, 
requiring standardized data sharing and standardized experimental 
protocols. 
Another key point that we feel is becoming strategic, is that 
emerging studies will include different techniques in the same ex-
perimental process. This requires integrated, comprehensive and 
very flexible solutions, based on the management of all tissue 
samples for general experimental process. This approach enables 
to share previously studied cohorts or to include previously de-
tected information and knowledge, taking advantage of well or-
ganized databases. 
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10. Appendix A 
To assess if and how initial calibration settings of the automatic 
system affect protein expression evaluations, we asked five pa-
thologists to independently calibrate the system (inter-variability 
test). We used antibodies against MIB1 and ECAD. One patholo-
gist set the calibration setting twice on one slide (intra-variability 
test). 
 
  
 
 
Figure 32 - Distribution of automatic evaluations for MIB1 percent-
ages (first row) and ECAD intensities (second row). The two col-
umns show data obtained with two different settings (two patholo-
gists).  
 
Output data distributions are shown in Figure 32. Variance tests 
(F test) among couples of evaluation data were performed. Data 
obtained for ECAD are shown in  
Table 17.  
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Table 17 - F-Test results for ECAD. P values are reported where 
variance tests were statistically significant. 
 
ECAD - Intensity      
 Path1 Path 2 Path 3 Path 4 Path 5 Factory 
Path 1   - - - - >0.05 
Path 2     - >0.05 - - 
Path 3       - - >0.05 
Path 4         >0.05 - 
Path 5           - 
Factory             
 
We then looked for within group discriminative powers of each of 
the markers. We used mean pooled values among replicates. Wil-
coxon test was applied. Results are listed in Table 18. 
 
Population: Benign=18; Stroma=5; Adenocarcinoma=18; Metas-
tatic PCA=9; WAP = 7; SmallCell=2. 
Table 18 – Wilkoxon test results. P-values are reported where vari-
ance tests were statistically significant. 
 BEN vs ADENO 
ADENO 
vs META 
ADENO 
vs WAP 
ADENO 
vs 
(META + 
WAP) 
META 
vs 
WAP 
SM_CE 
vs WAP 
STROMA 
vs BEN 
 MIB1 
Path 1 <0.001 <0.05 <0.01 - <0.05 - <0.001 
Path 2 <0.01 - <0.01 - <0.01 - <0.01 
Path 3 <0.001 <0.05 <0.01 - <0.01 - <0.05 
Path 4 <0.001 <0.01 <0.05 - <0.01 - - 
Path 5 <0.001 <0.05 <0.01 - <0.01 - - 
Path 5b <0.001 <0.01 - - <0.05 - 0.052 
Factory - <0.01 - - <0.001 - - 
 ECAD 
Path 1 - - - - - - - 
Path.2 - - - - - - - 
Path 3 - - - - - - - 
Path 4 - <0.05 - - <0.05 - - 
Path 5 - <0.05 - - - - - 
Factory  - - - - - - 
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Figure 33 - ECAD intensities obtained with each setting set plotted 
against histotype groups. Cases used (mean value of core section 
replicates). 
Based on the experiments we did, we observed that the distribu-
tion variance is not conserved when different settings are used. 
Output values are differently ‘spread’. 
The significance of mean differences between histotype groups is 
not always conserved. Intra-variability is also of some concern 
(see Path5 and Path5b on MIB1).  
Calibration settings may affect experiment results. 
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